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Abstract: Obesity and the associated comorbidities are a growing health threat worldwide. Adipose
tissue dysfunction, impaired adipokine activity, and inflammation are central to metabolic diseases
related to obesity. In particular, the excess storage of lipids in adipose tissues disturbs cellular
homeostasis. Amongst others, organelle function and cell signaling, often related to the altered
composition of specialized membrane microdomains (lipid rafts), are affected. Within this context, the
conserved family of annexins are well known to associate with membranes in a calcium (Ca2+)- and
phospholipid-dependent manner in order to regulate membrane-related events, such as trafficking
in endo- and exocytosis and membrane microdomain organization. These multiple activities of
annexins are facilitated through their diverse interactions with a plethora of lipids and proteins,
often in different cellular locations and with consequences for the activity of receptors, transporters,
metabolic enzymes, and signaling complexes. While increasing evidence points at the function of
annexins in lipid homeostasis and cell metabolism in various cells and organs, their role in adipose
tissue, obesity and related metabolic diseases is still not well understood. Annexin A1 (AnxA1) is a
potent pro-resolving mediator affecting the regulation of body weight and metabolic health. Relevant
for glucose metabolism and fatty acid uptake in adipose tissue, several studies suggest AnxA2 to
contribute to coordinate glucose transporter type 4 (GLUT4) translocation and to associate with the
fatty acid transporter CD36. On the other hand, AnxA6 has been linked to the control of adipocyte
lipolysis and adiponectin release. In addition, several other annexins are expressed in fat tissues, yet
their roles in adipocytes are less well examined. The current review article summarizes studies on the
expression of annexins in adipocytes and in obesity. Research efforts investigating the potential role
of annexins in fat tissue relevant to health and metabolic disease are discussed.
Keywords: annexins; adipose tissue; adiponectin; cholesterol; glucose homeostasis; inflammation;
insulin; lipid metabolism; obesity; triglycerides
1. Introduction
1.1. Obesity
In most countries, the increasing prevalence of obesity represents a rapidly growing risk factor
for chronic liver diseases, type 2 diabetes (T2D), cardiovascular diseases and most types of cancer.
The mechanisms contributing to obesity are multifactorial and are far from being completely understood.
Moreover, life style changes with less caloric intake and increased energy expenditure appear insufficient
to reduce body weight in the long term. Hence, the identification of the multiple processes that
contribute to excess adiposity is required to enact innovative strategies to combat this epidemic [1,2].
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Some key features and cellular machineries that contribute to increased and dysfunctional fat mass are
listed below.
Adipose tissue is central to the development of obesity and is composed of different cell populations
including fibroblasts, preadipocytes, mature adipocytes, macrophages, mesenchymal stem cells,
endothelial cells, and vascular smooth muscle cells, with cellular function as well as their quantity
being affected by obesity [1]. All these different cell types, through various mechanisms, contribute
to obesity and associated comorbidities, which has been reviewed in detail elsewhere [1–3]. In brief,
storage of nutrients and their mobilization for energy production are critical functions of adipose
tissue. Yet, increased lipolysis in obese fat tissue is closely associated with the development of
insulin resistance and T2D [1–3]. In addition, the excessive accumulation of fat in adipocytes due to
overnutrition can lead to an inflammatory response that creates further metabolic complications [3–5].
In fact, even the physical stress triggered by the swelling that occurs in adipocytes upon increased
fat accumulation seems to contribute to inflammation and insulin resistance [6]. In regard to the
inflammatory process, macrophages accumulate in adiposity and in response to environmental
signals in the fat tissue, undergo polarization to pro-inflammatory M1 macrophages [3]. In addition,
in adipose tissue other myeloid cells, as well as T- and B-lymphocytes, have been linked to macrophage
homeostasis and the inflammatory process associated with obesity [7]. Moreover, the growing tissue
is not appropriately supplied with oxygen causing hypoxia, which contributes to inflammation and
fibrosis. This pathological progress, adipose tissue fibrosis, hinders tissue growth and is linked to
metabolic impediments [3]. Further complexity is created by truncal or android fat distribution, which
was recently identified as an independent risk factor for metabolic diseases in obesity. Also, visceral and
subcutaneous adipose tissues differ in blood flow, cellular composition, adipocyte size and endocrine
function, thereby contributing differently to whole body physiology [2,3].
Additionally, the identification of brown fat in humans [8–10] has initiated new exciting research
in the field over the last decade, as its highly elevated expression of uncoupling proteins leads to the
production of heat, which favors weight loss [3,11]. Due to its therapeutic potential, the process of
browning has created great interest, where white fat cells become so-called beige or brite adipocytes,
acquiring characteristics of brown fat, in particular the upregulation of uncoupling proteins. Hence,
molecules targeting brown or brite fat to increase energy expenditure are being investigated for
their potential to reduce body weight and improve metabolic health [12]. Actually, besides increased
thermodynamic expenditure, the activation of brown adipose tissue additionally accelerated other
cardioprotective and clinically relevant events, such as clearance of plasma triglycerides, a process that
was dependent on the fatty acid transporter CD36 [13]. Furthermore, brown fat also contributed to
lipoprotein processing and the conversion of cholesterol to bile acids in the liver, enabling the removal
of excess cholesterol from the body [14]. Moreover, especially under thermogenic stimulation, brown
fat releases several bioactive factors with endocrine properties, including insulin-like growth factor I,
interleukin-6 (IL-6), or fibroblast growth factor-21, which influence hepatic and cardiac function,
contributing to improved glucose tolerance and insulin sensitivity [15–17].
Given that obesity is characterized by an increased accumulation of triglycerides, research in
the field over the last two decades has focussed on the dysregulation of the fatty acid metabolism.
However, obese adipocytes also accumulate calcium and cholesterol crystals, which was demonstrated
to contribute to oxidative stress and cell death [5]. On the other hand, plasma membrane cholesterol
was depleted in obese fat cells which probably impaired the function of cholesterol-rich membrane
microdomains (lipid rafts), causing an elevated release of C-C motif chemokine ligand 2 (CCL2), a major
chemoattractant for monocytes [18]. In other studies, inhibition of the Niemann-Pick type C1 (NPC1)
transporter, which facilitates cholesterol export from late endocytic (pre-lysosomal) and lysosomal
compartments, impaired insulin signaling and glucose uptake in adipocytes [19]. Cholesterol is also
essential for the proper functioning of endo- and exocytic vesicle transport, which control the release
of distinct adipokines like adiponectin [20], an anti-inflammatory plasma protein that improves insulin
sensitivity, but is reduced in obesity [21].
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A more detailed analysis of the various pathways listed above and affected in obese adipose
tissues clearly is essential to develop strategies to combat obesity. However, it would go beyond the
scope of this review to list all pathways contributing to adipose tissue dysfunction and we refer the
reader to other excellent articles [3,4,22]. In the following, we will summarize and focus on the current
understanding of how a group of evolutionary conserved proteins, the annexins, may influence fat
tissue function in health and disease.
1.2. Annexins
The annexin family in humans and vertebrates consists of twelve structurally related Ca2+-
and membrane binding proteins (AnxA1–AnxA11, AnxA13) [23,24]. All annexins contain a variable
N-terminus, followed by a conserved C-terminal domain with four (or eight in AnxA6) annexin repeats
(Table 1). Each of these repeats encodes for Ca2+ binding sites, allowing annexins to rapidly translocate
to phospholipid-containing membranes in response to Ca2+ elevation [23,25,26]. Hence, annexin
functions are intimately dependent on their dynamic and reversible membrane binding behaviour.
Nevertheless, their similar structure, phospholipid-binding properties, overlapping localizations,
and shared interaction partners have made it difficult to elucidate their precise functions. Yet,
despite in vivo studies in knock-out (KO) models strongly suggesting redundancy within the annexin
family, specific functions of individual annexins have been identified [23,25–31]. Interestingly, besides
often subtle differences in their spatio-temporal and Ca2+-sensitive membrane binding behaviour to
negatively charged phospholipids, the diversity of N-terminal interaction partners, affinity to other
lipids, including phosphatidylinositol-4,5-bisphosphate, cholesterol and ceramide, posttranslational
modifications, and most relevant for this review, their differential expression patterns seem to facilitate
opportunities to create functional diversity within the annexin family [23,25–31]. The subsequent
chapters will review recent knowledge on the expression of individual annexins in adipose tissue, with
quite diverse implications for adipocyte and macrophage function in health and obesity.
Table 1. Domain structure, expression patterns, and potential functions of annexins expressed in
adipose tissue. The different length of the N-terminal leader and C-terminal annexin repeats 1–4
(1–8 for AnxA6) for each annexin are indicated. AnxA13a differs from AnxA13b by a 41 amino acid
N-terminal deletion [32]. Relevant references for each annexin are listed. AnxA, annexin; GLUT4,
glucose transporter type 4; HFD, high-fat diet; HSL, hormone-sensitive lipase; SV, stromal-vascular
fraction; TZDs, thiazolidinediones. N/A, not available.
Name Structure Adipose Tissue Expression Function References
A. Prominent Annexins in Adipose Tissue.
AnxA1
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partners, affinity to other lipids, including phosphatidylinositol-4,5-bisphosphate, cholesterol and 
ceramide, posttranslational modifications, and most releva t for this review, their differential 
expression patterns seem to facilitate opportunities to create functional diversity within the annexin 
family [23,25–31]. The subsequent chapters will review recent knowledge on the expression of 
individual annexins in adipose tissue, with quite diverse implications for adipocyte and macrophage 
function in health and obesity. 
Table 1. Domain structure, expression patterns, and potential functions of annexins expressed in 
adipose tissue. The different length of the N-terminal leader and C-terminal annexin repeats 1–4 (1–8 
for AnxA6) for each annexin are indicated. AnxA13a differs from AnxA13b by a 41 amino acid N-
terminal deletion [32]. Relevant references for each annexin are listed. AnxA, annexin; GLUT4, 
l cose transporter type 4; HFD, high-fat diet; HSL, hormone-sensitive lipase; SV, stromal-vascular 
fraction; TZDs, thiazolidinedio es. N/A, not available. 
Name Structure Adipose Tissue Expression Function References 
A. Prominent Annexi s in dipose Tissue. 
AnxA1 
 
adipocytes, SV, 
visceral fat, 
subcutaneous fat, 
obesity , 
HFD , TZDs  
insulin response ,  
obesity , 
leptin , 
inflammation  
[33–45] 
AnxA2 
 
adipocytes, 
endothelial cells, 
macrophages, 
subcutaneous fat, 
epididymal fat, 
mesenteric fat, 
guggulsterone , 
TZDs  
GLUT4 translocation, 
insulin response, glucose 
uptake, CD36-mediated 
fatty acid uptake, 
inflammation , 
macrophage infiltration , 
HSL activation 
[46–60] 
AnxA6 
 
adipocytes, 
macrophages, 
subcutaneous fat, 
perirenal fat, 
epididymal fat, 
visceral fat,   
brown fat, 
preadipocyte proliferation 
, triglyceride storage  , 
adiponectin release , 
cholesterol-dependent 
caveolae formation, 
cholesterol-dependent 
GLUT4 translocation, 
[2,35,47,61–74] 
adipocytes, SV, visceral fat,
subcutane f t, obesity ↑,
HFD ↑, TZDs ↑
insulin response ↑,
obesity ↓,
leptin ↓,
inflammation ↓
[33–45]
AnxA2
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cholesterol-dependent GLUT4
translocation,
cholesterol-dependent
adiponectin secretion?
[2,35,47,61–74]
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Table 1. Cont.
Name Structure Adipose Tissue Expression Function References
B. Other Annexins in Adipose Tissue.
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AnxA1 (previously known as lipocortin 1) is expressed in most cell types, and abundant in 
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actin dynamics and regulation of metabolic enzymes related to cell growth, differentiation, motility 
and apoptosis [25,26,92–94]. In addition, AnxA1 has a prominent extracellular function, acting as an 
anti-inflammatory, pro-resolving protein which exerts its effects via binding to the formyl peptide 
receptor 2 (FPR2). Both molecules are induced by glucocorticoids and contribute to the beneficial 
activities of these anti-inflammatory drugs [39,42]. 
The inflammation-related functions of FPR2 are diverse and complex, with multiple FPR2 
ligands exercising various and sometimes opposite activities [36,95]. While the loss of FPR2 reduced 
inflammation, the overall FPR2 activity in fat tissue in vivo is most likely the net result of the distinct 
expression patterns and the localized distribution of different FPR2 ligands in this tissue [36]. 
Importantly, resolvin D1 and lipoxin A4, both bioactive lipid mediators that have been identified in 
adipose tissue, are agonists of this G-protein coupled receptor [96,97]. These lipids have anti-
inflammatory activities and highlight the requirement to fine-tune the balance of ligands with 
opposing activities, in order to activate the immune response and thereby accelerate the termination 
of inflammation [96]. 
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fat, intraabdominal fat
adipocyte
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lipid accumulation?
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opposing activities, in order to activate the imm n  response and thereby accelerate the termination
f inflamma ion [96]. 
SV, s bcutaneous fat,
intraabdominal fat
fat deposition, storage or
mobilization?
[35,78],
Geo Profiles;
DataSet Record
GDS2818
AnxA7
Int. J. l. Sci. 2019, 20, x FOR PEER REVIEW 4 of 22 
 
obesity , HFD , 
oxidative stress  
cholesterol-dependent 
adiponectin secretion? 
B. Other Annexins in Adipose Tissue. 
AnxA3 
 
adipocytes, SV, 
subcutaneous fat, 
intraabdominal fat 
adipocyte  
differentiation , 
lipid accumulation? 
[75–77], Geo 
Profiles; 
DataSet 
Record 
GDS2818 
 
AnxA5 
 
SV, subcutaneous fat, 
intraabdominal fat 
fat deposition, storage or 
mobilization? 
[35,78], 
Geo Profiles; 
DataSet 
Record 
GDS2818 
 
AnxA7 
 
SV, subcutaneous fat, 
intraabdominal fat 
infiltration of immune 
cells in dysfunctional 
adipose tissue? 
[79–83], Geo 
Profiles; 
DataSet 
Record 
GDS2818 
AnxA8 
 
adipocytes, SV, 
subcutaneous fat, 
intraabdominal fat 
cholesterol-dependent 
caveolae formation, 
cholesterol-dependent 
GLUT4 translocation, 
cholesterol-dependent 
adiponectin secretion? 
[84–89], Geo 
Profiles; 
DataSet 
Record 
GDS2818 
C. Insufficiently Studied Annexins in Adipose Tissue. 
AnxA4 
 
N/A lipolysis? [90] 
9 
 
/  ?  
AnxA10 
 
adipocytes, SV, subcutanous 
fat, intraabdominal fat ?  
AnxA11 
 
adipocytes, SV, subcutanous 
fat, intraabdominal fat 
fatty acid release, 
adipokine secretion? [91] 
AnxA13a 
 
N/A ?  
AnxA13b 
 
N/A ?  
2. nnexin Expression Patterns in Adipose Tissue and Their Potential Functions in Obesity 
2.1. Annexin A1 (AnxA1) 
AnxA1 (previously known as lipocortin 1) is expressed in most cell types, and abundant in 
macrophages, neutrophils, the nervous and endocrine system [23,27,92]. Like other annexins, AnxA1 
is found at multiple locations inside cells, including the plasma membrane, endosomal and secretory 
vesicles, the cytoskeleton and the nucleus, participating in membrane transport, signal transduction, 
actin dynamics and regulation of metabolic enzymes related to cell growth, differentiation, motility 
and apoptosis [25,26,92–94]. In addition, AnxA1 has a prominent extracellular function, acting as an 
anti-inflammatory, pro-resolving protein which exerts its effects via binding to the formyl peptide 
receptor 2 (FPR2). Both molecules are induced by glucocorticoids and contribute to the beneficial 
activities of these anti-inflammatory drugs [39,42]. 
The inflammation-related functions of FPR2 are diverse and complex, with multiple FPR2 
ligands exercising various and sometimes opposite activities [36,95]. While the loss of FPR2 reduced 
inflammation, the overall FPR2 activity in fat tissue in vivo is most likely the net result of the distinct 
expression patterns and the localized distribution of different FPR2 ligands in this tissue [36]. 
Importantly, resolvin D1 and lipoxin A4, both bioactive lipid mediators that have been identified in 
adipose tissue, are agonists of this G-protein coupled receptor [96,97]. These lipids have anti-
inflammatory activities and highlight the requirement to fine-tune the balance of ligands with 
opposing activities, in order to activate the immune response and thereby accelerate the termination 
of inflammation [96]. 
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AnxA1 (previously known as lipocortin 1) is expressed in most cell types, and abundant in 
macrophages, neutrophils, the nervous and endocrine system [23,27,92]. Like other annexins, AnxA1 
is found at multiple locatio s inside cells, including the pla ma me bran , endo omal and secretory
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actin dyna ics and regula ion of metabolic enzymes related to c ll g owth, diff entiatio , motilit  
and apop osis [25,26,92–94]. In addition, AnxA1 h s a pro inent extracellula  function, cting as an 
nt -inflamma ry, pr -resolving protein which ex rts ts effects via binding o the formyl peptide 
receptor 2 (FPR2). Both molecules are induced by glucocorticoids and cont b t  t  he benef cial 
c vities of these anti-inflamm tory drugs [39,42]. 
The infl mmati n-r lat d functions of FPR2 are diverse and complex, with multiple FPR2 
ligands exercising various and sometimes opposite activities [36,95]. While the loss of FPR2 redu ed 
inflammation, the overal  FPR2 activity in fat tissue in vivo is most likely the net result of he distinct
expres ion p tterns and th  localized distribution of d ffer nt FPR2 ligands n this ssue [36]. 
Importan ly, resol in D1 and lipoxin A4, bo h bioactive lip d ediators t at hav  been identified in 
adipose tissue, are gonists of this G-pro e n c upled receptor [96,97]. Thes  lipids av  a ti-
inflammatory acti ities and high ight the requ rement to fin -tune the bal nce of l ga ds with 
op sing activities, in rder to ac ivate the immune response an  thereby ccelerate the termin tio  
of inflammation [96]. 
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2.1. Annexin A1 (AnxA1) 
A xA1 (previously kno n as lipocortin 1) is expressed in ost cell types, and abundant in 
acrophages, neutrophils, the nervous and endocrine syste  [23,27,92]. Like other annexins, AnxA1 
is found at ultiple locations inside cells, including the plas a e brane, endoso al and secretory 
vesicles, the cytoskeleton and the nucleus, participating in e brane transport, signal transduction, 
actin dyna ics and regulation of etabolic enzy es related to cell gro th, differentiation, otility 
and apoptosis [25,26,92–94]. In addition, AnxA1 has a pro inent extracellular function, acting as an 
anti-infla atory, pro-resolving protein hich exerts its effects via binding to the for yl peptide 
receptor 2 (FPR2). Both olecules are induced by glucocorticoids and contribute to the beneficial 
activities of these anti-infla atory drugs [39,42]. 
The infla ation-related functions of FPR2 are diverse and co plex, ith ultiple FPR2 
ligands exercising various and so eti es opposite activities [36,95]. hile the loss of FPR2 reduced 
infla ation, the overall FPR2 activity in fat tissue in vivo is ost likely the net result of the distinct 
expression patterns and the localized distribution of different FPR2 ligands in this tissue [36]. 
I portantly, resolvin D1 and lipoxin A4, both bioactive lipid ediators that have been identified in 
adipose tissue, are agonists of this G-protein coupled receptor [96,97]. These lipids have anti-
infla atory activities and highlight the require ent to fine-tune the balance of ligands ith 
opposing activities, in order to activate the i une response and thereby accelerate the ter ination 
of infla ation [96]. 
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2. Annexin Expression Patterns in Adipose Tissue and Their Potential Functions in Obesity 
2.1. Annexin A1 (AnxA1) 
AnxA1 (previously known as lipocortin 1) is expressed in most cell types, and abundant in 
macrophages, neutrophils, the nervous and endocrine system [23,27,92]. Like other annexins, AnxA1 
is found at multiple locations inside cells, including the plasma membrane, endosomal and secretory 
vesicles, the cytoskeleton and the nucleus, participating in membrane transport, signal transduction, 
actin dynamics and regulation of metabolic enzymes related to cell growth, differentiation, motility 
and apoptosis [25,26,92–94]. In addition, AnxA1 has a prominent extracellular function, acting as an 
anti-inflammatory, pro-resolving protein which exerts its effects via binding to the formyl peptide 
receptor 2 (FPR2). Both molecules are induced by glucocorticoids and contribute to the beneficial 
activities of these anti-inflammatory drugs [39,42]. 
The inflammation-related functions of FPR2 are diverse and complex, with multiple FPR2 
ligands exercising various and sometimes opposite activities [36,95]. While the loss of FPR2 reduced 
inflammation, the overall FPR2 activity in fat tissue in vivo is most likely the net result of the distinct 
expression patterns and the localized distribution of different FPR2 ligands in this tissue [36]. 
Importantly, resolvin D1 and lipoxin A4, both bioactive lipid mediators that have been identified in 
adipose tissue, are agonists of this G-protein coupled receptor [96,97]. These lipids have anti-
inflammatory activities and highlight the requirement to fine-tune the balance of ligands with 
opposing activities, in order to activate the immune response and thereby accelerate the termination 
of inflammation [96]. 
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.1. nexin 1 ( nx 1) 
x 1 ( revio sly k o  as li ocorti  1) is ex resse  i  ost cell ty es, a  ab a t i  
acro ages, e tro ils, t e ervo s a  e ocri e syste  [23,27,92]. ike ot er a exi s, x 1 
is fo  at lti le locations i si e cells, i cl i g t e las a e bra e, e oso al a  secretory 
vesicles, t e cytoskeleto  a  t e cle s, artici ati g i  e bra e tra s ort, sig al trans ction, 
acti  y a ics a  reg latio  of etabolic e zy es relate  to cell gro t , iffere tiation, otility 
a  a o tosis [25,26,92–94]. I  a itio , x 1 as a ro i e t extracell lar f ctio , acti g as a  
a ti-i fla atory, ro-resolvi g rotei  ic  exerts its effects via bi i g to t e for yl e ti e 
rece tor 2 (F 2). ot  olec les are i ce  by gl cocorticoi s a  co tribute to t e be eficial 
activities of t ese a ti-i fla atory r gs [39,42]. 
e i fla atio -relate  f ctio s of F 2 are iverse a  co lex, it  lti le F 2 
liga s exercisi g vario s a  so eti es o osite activities [36,95]. ile t e loss of F 2 re ce  
i fla atio , t e overall F 2 activity i  fat tiss e i  vivo is ost likely t e et res lt of t e isti ct 
ex ressio  atter s a  t e localize  istrib tio  of iffere t F 2 liga s i  t is tiss e [36]. 
I orta tly, resolvi  1 a  li oxi  4, bot  bioactive li i  e iators that ave bee  i e tifie  i  
a i ose tiss e, are ago ists of t is - rotei  co le  rece tor [96,97]. ese li i s have anti-
i fla atory activities a  ig lig t t e req ire e t to fi e-t e t e bala ce of ligan s it  
o posi g activities, i  or er to activate t e i e res o se a d t ereby accelerate t e ter i ation 
of i fla atio  [96]. 
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2.1. nnexin 1 ( nx 1) 
nx 1 (previously kno n as lipocortin 1) is expressed in ost cell types, and abundant in 
acrophages, n utrophils, the ervous and e docrin  syste  [23,27,92]. Like other nexins, nx 1 
is found at ultiple locatio s inside cells, inclu ing the plas a e brane, endoso al and ecretory 
vesicles, the cytosk leton a d the nu leus, participating in me brane transport, ign l tra ducti n, 
actin dyna ics and r gul tion of etabolic enzy es related to cell gro th, differe tiatio , otilit  
nd apoptosis [25,26,92–94]. I  addition, nx 1 has a pro inent extracellular function, acting as an 
ti-infla atory, pro-resolving protein hich exerts its effects via binding to the for yl peptide 
receptor 2 (FPR2). Both lecules are i duced by glucocorticoids nd co trib te to the ben ficial 
activities of these anti-infla atory drugs [39,42]. 
The infla tion-related functions of FPR2 are diverse and co plex, ith ultiple FPR2 
ligands xercising various nd so eti e  pposite activities [36,95]. hile the loss of FPR2 r duced 
infla ation, the overall FPR2 activity in fat tis u  in vivo i  ost likely the n t re ult of the distinct 
expression patterns a d the localized distribution of ifferent FPR2 ligands in this tissue [36]. 
I ortantly, resol in 1 and lipoxin 4, b th bioactive lipid ediators that have been identified in 
adi se tissue, are agonists of this -pr tein coupl d receptor [96,97]. T es  lipids ave a ti-
infla atory acti ities and highlight the r quire ent to fine-tune the balance of liga ds ith 
op osing activities, in order to activate the i n  response a d thereby accelerate the ter inatio  
f infla ation [96]. 
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2.1. exin A1 (AnxA1)
xA1 (previously known as lip ortin 1) is express d in most cell types, and abundant in
macrophages, n utrophils, th nervous a d endocrine sy em [23,27,92]. Like o her annexins, AnxA1
is found at multiple locations inside cells, including the plasma membrane, end somal and secretory
vesicles, the cytoskeleton and the nucleus, participating in membrane tra sp rt, signal transduction,
acti na ics and gulation f metabolic enzyme rel t t cell grow h, diff rentiation, motility
and pto is [ 5,26, 2–94]. In d ition, AnxA1 has a p ominent ex r c llular function, acting as an
anti-inflammatory, pro-resolving protein which exerts its effects via binding to the formyl peptide
receptor 2 (FPR2). Both mole ules are induce by glucocorticoids and contribute to the beneficial
acti iti s of th se a ti-infl mmatory drugs [39,42].
infla m tion-related funct ns of FPR2 are diverse and com l x, with multiple FPR2
ligands exe cising various a d sometimes o posite activi ies [36,95]. While the loss of FPR2
re uced nflamm tion, the overall FPR2 activity in fat tissue in vivo is most likely the net result
of the distinc expression patterns and the localize distributio of iffere t FPR2 ligands in this
tissue [36]. Importa tly, resolvin D1 and li oxin A4, both bio ctive lipid mediators that have been
identified in adipose tissue, are agonists of this G-protein coupled receptor [96,97]. These lipids have
anti-inflammatory activities and highlight the requirement to fine-tune the balance of ligands with
opposing activities, in order to activate the immune response and thereby accelerate the termination of
inflammation [96].
Recent studies suggest that the AnxA1/FPR2 axis is highly relevant for obesity and related inflammation,
as well as other complications, such as insulin resistance, T2D and atherosclerosis [36,37,41,42,45].
As levels of FPR2 and its ligands critically influence strength of biological response, it is interesting
to note that in obese mice, adipose tissue FPR2 mRNA and resolvin D1 levels were decreased [95].
Most relevant for AnxA1 in adipose tissue, the FPR2 peptide agonist WKYMVM, which is derived
from the N-terminus of AnxA1, greatly enhanced the insulin response of diet-induced obese mice [45].
Int. J. Mol. Sci. 2019, 20, 3449 5 of 23
Somewhat unexpectedly, FPR2 deficiency improved the metabolic health of mice that were
fed a high fat diet [36]. In this study, FPR2 was increased in fat of diet-induced obese mice and
diabetic, leptin-receptor mutated, animals. Loss of FPR2 in macrophages blocked polarization into
pro-inflammatory M1 macrophages [36]. FPR2 knock-out mice were less obese and higher thermogenesis
in skeletal muscle was most likely responsible for enhanced energy expenditure [36]. Although the
lack of FPR2 signalling events induced by ligands other than AnxA1 probably also contribute to the
phenotype of the FPR2 knock-out mice described above, one can speculate that up- or downregulation
of AnxA1 may also have profound effects on FPR2-dependent energy metabolism in adipose tissue.
In this context, it is still unclear which cell types contribute to extracellular AnxA1 levels in adipose
tissue. In fat tissues, AnxA1 was more abundant in the stromal-vascular fraction than in adipocytes [43],
indicating that infiltrating monocytes and macrophages expressing AnxA1 may represent the main
source of extracellular AnxA1 in fat [39]. In support of this hypothesis, when these immune cells
became activated, AnxA1 translocated to the cell surface and was secreted [39].
Besides the contribution of non-adipocytes to AnxA1 levels in fat mass, its expression appears
tightly regulated during adipocyte differentiation, as murine 3T3-L1 adipogenesis identified AnxA1
mRNA and protein downregulation [44]. In contrast, in mature adipocytes from patients with Simpson
Golabi Behmel syndrome, an overgrowth disorder leading to craniofacial, skeletal, cardiac, and renal
abnormalities, AnxA1 mRNA and protein amounts were approximately 65-fold higher compared to
their corresponding preadipocytes. As FPR2 levels were markedly reduced in this model, it remains
to be determined if drastically upregulated AnxA1 expression alters the repertoire and availability
of other extracellular FPR2 ligands and impacts on FPR2 activity [38,44]. Simpson Golabi Behmel
syndrome is associated with glypican-3 loss-of-function mutations [98], implicating a possible link
between adipocyte AnxA1 expression and this poorly characterized cell surface proteoglycan. However,
a more likely explanation could be the higher concentration of glucocorticoids used in this study,
possibly causing an elevation of AnxA1 levels irrespective of adipogenesis. The analysis of purified
preadipocytes and mature cells may be an appropriate approach to better define transcriptional and
post-transcriptional regulation of AnxA1 expression during adipogenesis.
The therapeutic potential of AnxA1 is further underscored by its upregulation in the subcutaneous
fat of obese men given rosiglitazone for two weeks [33]. Glitazones are insulin sensitizers and agonists
of peroxisomal proliferator-activated receptor-γ (PPARγ), a master regulator of adipogenesis [99].
AnxA1 is a target gene of this transcription factor in breast cancer cells [100] and most likely in
numerous other cell types [39,101]. Whether this PPARγ-dependent transcriptional control of the
AnxA1 promoter also applies for adipocytes needs additional studies.
Further documenting a relationship between AnxA1 and obesity, AnxA1 mRNA was strongly
increased in adipose tissue of mice on a high fat diet [34]. This upregulation was observed in
both leptin- and IL-6-deficient animals, strongly pointing at transcriptional pathways not directly
regulated by these factors being responsible for AnxA1 upregulation in a lipid-rich environment [34].
AnxA1 mRNA expression was also higher in visceral adipose tissues of obese compared to lean
children [102]. Proteome assessment of adipocytes isolated from subcutaneous fat of young and old
overweight patients revealed higher AnxA1 protein levels in the latter [35]. Hence, as older subjects
more often suffer from insulin resistance and cardiovascular disease, these findings further support a
function of AnxA1 in metabolic health. Interestingly, under inflammatory conditions, AnxA1 may
undergo protease-mediated degradation, leading to pro-inflammatory AnxA1 fragments that lack the
FPR2-binding motif in the N-terminal AnxA1 region [103]. Indeed, cleaved AnxA1 was more abundant
in adipose tissues of obese individuals independent of their insulin resistance status [40].
Whole body physiology critically influences adipose tissue function and in the following, we will
briefly summarize some observations that could impact on AnxA1 levels and functions in fat tissue.
In contrast to upregulated adipose AnxA1 levels in obesity-related disease settings listed above [33,34,102],
one study identified that circulating levels of AnxA1 were decreased in obesity [38]. Yet, more recent
research described that serum AnxA1 amounts increased with body mass index (BMI) and positively
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correlated with IL-6 [40]. In the same report, an association of serum AnxA1 levels with T2D was not
apparent [40]. The opposing outcome of these two studies clearly illustrates that further research is
needed to resolve the role of AnxA1 in adiposity and metabolic diseases.
Over the years, many studies have established that dysregulation of the inter-organ cross-talk
beween adipose tissue and other metabolic organs contribute to significant changes in energy
homeostasis, glucose and lipid metabolism in obesity and associated complications. Adipose tissue
releases numerous adipokines that influence liver, muscle and pancreas physiology, which in turn,
have potential to modify glucose and lipid handling in fat tissue [3,4]. This may also include alterations
in AnxA1 expression, secretion, and protein stability, which may impact on serum AnxA1 levels or
influence other AnxA1-related biological activities with indirect effects on adipocytes. For example,
non-alcoholic fatty liver disease is commonly diagnosed in the obese and is a spectrum ranging from
benign liver steatosis to hepatitis and fibrosis [21]. Hepatic AnxA1 protein expression was reduced
in patients with bridging fibrosis when compared to those with mild disease [104]. In mice fed a
methionine-choline-deficient diet to induce non-alcoholic steatohepatitis (NASH), hepatic AnxA1
protein levels were nevertheless increased [104]. While these findings may suggest a link between
AnxA1 expression levels and hepatic neutral lipid accumulation, oleate-induced lipid storage was
normal in AnxA1-overexpressing Huh7 hepatocytes [61]. Accordingly, hepatic triglycerides levels
were also comparably induced in murine NASH of wild type and AnxA1-deficient mice [104].
Yet irrespective of neutral lipid storage, liver inflammation and fibrosis were clearly enhanced in
AnxA1 KO-animals [104].
AnxA1 was expressed in liver macrophages and contributed to anti-inflammatory M2 macrophage
polarization and IL-10 production. Accordingly, macrophages developed into a pro-inflammatory M1
phenotype in the AnxA1 null animals [104]. Galectin-3 is produced by activated macrophages and
contributes to liver fibrosis, and recombinant AnxA1 prevented galectin-3 expression [104]. Strikingly,
AnxA1 protected the liver from NASH in this experimental model, which is characterized by body
weight loss [104]. Furthermore, inhibition of hepatitis C virus replication by AnxA1 showed a protective
role in the development of chronic liver disease [105]. Again, steatosis grade was not changed by
AnxA1 in the liver cells [105]. Hence, these studies suggest protective roles for AnxA1 in liver function,
which could also support a healthy communication with adipose tissue.
Beneficial effects of AnxA1 were also described in muscle and pancreatic beta-cells, both highly
relevant for glucose homeostasis [106]. The saturated fatty acid palmitate, which is elevated in
the plasma of obese patients, induced insulin resistance and suppressed AnxA1 expression in L6
myotubes [45,107]. On the other hand, AnxA1 released from mesenchymal stromal cells improved
the glucose-induced insulin release of human islets in a co-culture model demonstrating protective
functions on pancreatic beta-cells [108].
Taken together, most of the data summarized above point towards disease-preventing activities of
AnxA1 in obesity (Table 1). In further support of this model, AnxA1 null mice were in fact more obese,
had larger adipocytes and increased leptin levels when fed a high fat diet [34]. Common measures that
occur with high fat diet feeding, such as upregulation of lipolytic enzymes and downregulation of
11-beta hydroxysteroid dehydrogenase type 1, was only significant in fat tissues of the obese wild type
animals [34]. Corticosterone levels were higher in the AnxA1-deficient animals and may have further
promoted adiposity in these mice [34]. Moreover, the high fat diet fed AnxA1 KO-mice displayed
elevated glucose and insulin levels, and were less insulin-sensitive. Interestingly, despite the prominent
anti-inflammatory features of AnxA1 discussed above, adipose tissue inflammation was not induced
in these mice [34]. The exacerbation of obesity-associated metabolic diseases in AnxA1 null mice was
confirmed in a further study. The treatment of these mice with recombinant human AnxA1 reduced
body weight, fat mass, and liver steatosis [41].
Finally, others analyzed AnxA1 null mice fed a control chow diet. Body weight and adipocyte
size were normal, whereas epididymal fat mass was reduced in AnxA1-deficient animals [43].
Catecholamine-induced rise in cAMP levels and lipolysis were more pronounced in adipose tissue
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explants of the control animals [43]. Adipose tissue explants from the AnxA1 KO-mice further displayed
a lower production of IL-6, which was not attributed to a decline in the number of macrophages in
intra-abdominal fat pads [43].
Overall, the studies summarized above indicate AnxA1 as a metabolism-improving molecule in
models of metabolically stressed animals (Figure 1, Table 1). This may provide exciting therapeutic
opportunities [37,39,41,42,45,104], but more research—exploring for instance the comparison of energy
expenditure measurements in controls and the AnxA1 null mice on chow and high fat diets [34,41]—is
still needed to better understand the various molecular pathways regulated by AnxA1 in adipose tissues.
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Figure 1. The multiple roles of AnxA1 in metabolism. AnxA1 increased insulin release of pancreatic
beta-cells [108] and improved insulin response of skeletal muscle and whole body insulin sensitivity, thus
lowering circulating glucose and insulin levels [34,45]. AnxA1 further ameliorated hepatic inflammation
and fibrosis in a murine NASH model [104]. AnxA1 null mice were more obese, produced more leptin
and had higher adipose tissue lipolysis, inflammation and corticosterone levels. AnxA1 did not alter
the recruitment of adipose tissue macrophages [34].
2.2. Annexin A2 (AnxA2)
xA2 is ubiquitously expressed and most abundant in endothelial cells, monocytes and
macrophages. In addition, AnxA2 is also often upregulated in cancers [23,25,94,109–111]. Most AnxA2
proteins form a heterotetrameric complex with p11, a member of the S100 protein family, at the
plasma membrane and intracellular compartments, while only small amounts of AnxA2 monomer are
present in the cytosol, endosomes and nucleus. In these multiple locations, AnxA2 contributes to the
regulation of endo-/exocytic membrane transport, microdomain organization, membrane repair and
nuclear transport, relevant for many different cellular activities [23,25,26,93,94,109]. Also, extracellular
AnxA2 activities related to fibrinolysis and not discussed further in this review have been well
documented [109–112].
AnxA2 is expressed in the adipose tissues of humans and rodents [53,57] and has been linked
with two prominent aspects of adipocyte function (Table 1). Firstly, several studies implicated AnxA2
in glucose homeostasis, in particular the insulin-inducible translocation of GLUT4, the main glucose
transporter in adipocytes, from intracellular compartments to the cell surface. In one study, the silencing
of AnxA2 in 3T3-L1 adipocytes improved insulin sensitivity and glucose uptake [59]. In striking
contrast, others reported that AnxA2 inhibition or depletion, using antibodies or knockdown approaches,
strongly reduced insulin-inducible GLUT4 translocation [51]. As insulin exposure promoted GLUT4,
but not AnxA2, trafficking to the cell surface [55], it appears unlikely that direct interaction or GLUT4
translocation along AnxA2-positive vesicles occurs. Alternatively, the underlying mechanism could
involve a possible role of AnxA2 in insulin signaling through the modulation of insulin receptor
internalization [46]. Indeed, the fact that insulin induced AnxA2 phosphorylation [46,56,60], AnxA2
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sumoylation [50], and enhanced AnxA2 secretion [60] further indicates that the expression, localization
and activity of AnxA2 is closely connected to insulin signaling and glucose handling in adipocytes.
Hence, further studies are needed to clarify these current gaps of knowledge and discrepancies.
Secondly, AnxA2 has also been associated with fatty acid accumulation. In fact, in endothelial cells
and adipocytes of white adipose tissue, AnxA2 was critical for the cellular uptake of fatty acids. AnxA2
was found to bind prohibitin and the fatty acid transporter CD36 in both cell types, and assembly of
this complex at the plasma membrane was enforced by the presence of fatty acids [57]. This protein
complex not only improved fatty acid uptake in these two often neighbouring cell types, but also
enabled the transport of fatty acids from the endothelium to adipocytes. In further support of these
observations, palmitate-inducible expression of inflammatory genes like IL-6, IL-1 beta and tumor
necrosis factor alpha was markedly diminished upon AnxA2 suppression, while AnxA2 overexpression
amplified the proinflammatory capacity of this saturated fatty acid [59].
Several in vivo studies addressed the aforementioned potential roles of AnxA2 in glucose and
fatty acid metabolism (Figure 2). However, AnxA2 null mice had reduced steady-state glucose levels
and a normal glucose tolerance [57]. As the glucose uptake of white adipose tissues was comparable in
the control and AnxA2-deficient animals, it was concluded that AnxA2 did not have a central function
in GLUT4 translocation in vivo. On the other hand, AnxA2-deficient animals had a delayed clearance
of infused fatty acids, indicating that the lack of AnxA2 compromised CD36-mediated removal of
fatty acids from the bloodstream [57]. Given that thermogenic activation of brown adipose tissue
accelerated CD36-dependent clearance of plasma triglycerides [13], and palmitoylation-dependent
CD36 localization and trafficking in adipose tissue being sensitive to acute cold exposure [113],
testing cold tolerance in AnxA2 KO-mice in future studies could provide further critical insight.
Taken together, these findings might point at AnxA2 contributing to a more rapid clearance of lipids
and the improvement of postprandial hyperlipidemia.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 12 of 22 
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Figure 2. The diverse roles of AnxA2 and AnxA6 in adipose tissue function. AnxA2 improves
uptake and storage of fatty acids [57] and may have a role in glucose uptake and adipose tissue
inflammation [51,59]. On the other hand, AnxA6 modulates lipolysis and adiponectin secretion [68].
More recently, others investigated adenoviral-mediated AnxA2 up- or downregulation in mice
fed a high fat diet. Animals with low AnxA2 levels had reduced body weight at the end of the study,
displaying improved fasting blood glucose and insulin levels, as well as glucose and insulin tolerance.
Overexpression of AnxA2 did not change any of these parameters. In addition, AnxA2 depletion
was associated with less adipose tissue macrophages and inflammation, which was enhanced by
AnxA2 overexpression [59]. Hence, several AnxA2 functions observed in cell-based studies might be
relevant in stress-induced conditions in vivo, and, as outlined above, cell and animal studies support an
involvement of AnxA2 in adipose tissue function. In line with these observations, expression studies in
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humans and animal models suggest that AnxA2 levels are tightly regulated, often responding to changes
in whole body and adipose tissue physiology. For instance, AnxA2 was detected in preadipocytes
and was modestly induced during 3T3-L1 adipogenesis [54]. Guggulsterone, a natural drug which
inhibits adipocyte differentiation and induces apoptosis, increased AnxA2 expression in these cells [54].
While AnxA2 mRNA remained unchanged, post-translational processing of AnxA2 protein was
induced by guggulsterone [54], indicating that truncated AnxA2 isoforms may exert so far unknown
inhibitory functions during adipogenesis. However, in another study, troglitazone-induced PPARγ
activation, which promotes adipocyte differentiation [99], upregulated AnxA2 mRNA and protein
expression in 3T3-L1 adipocytes [51]. Likewise, the PPARγ agonist rosiglitazone also induced AnxA2
levels in subcutaneous fat of obese but otherwise healthy men. Together with the abovementioned
studies suggesting AnxA2 to promote glucose and fatty acid uptake, one can speculate that this
drug-induced upregulation of AnxA2 may contribute to the beneficial therapeutic effects of the
rosiglitazone-induced lowering of fasting insulin, glucose, and free fatty acids in plasma [33].
Interestingly, in murine adipose tissue AnxA2 protein levels were approximately two-fold higher
in large compared to small adipocytes. This differential expression pattern was abrogated in fat-specific
insulin receptor knock-out mice [47]. As the increased size of adipocytes is associated with an
elevated capacity for insulin-inducible neutral lipid storage, this further supports a function of AnxA2
upregulation in insulin-dependent metabolic changes during adipocyte differentiation and growth.
Indeed, a comparison of wild type and AnxA2-deficient mice revealed that AnxA2 was essential for
adipocyte growth, whereas adipogenesis was unaffected by the loss of AnxA2 [57].
Proteomic approaches to identify changes in weight loss and physical activity identified altered
AnxA2 levels in adipose tissue. Although a two-week high-intensity intermittent training of overweight
men neither improved BMI nor the parameters of insulin sensitivity, the inflammatory marker IL-6,
as well as AnxA2 and fatty acid synthase were significantly reduced in subcutaneous fat [53]. Likewise,
dietary changes, such as a low-fat, high-complex carbohydrate diet supplemented with long-chain
n-3 polyunsaturated fatty acids not only improved glucose and fatty acid metabolism, but also
downregulated AnxA2 expression in subcutaneous fat [52]. In contrast, a five week very low calorie
diet improved metabolic health and BMI of obese subjects, yet AnxA2 and GLUT4 levels increased,
whereas CD36 expression declined, in subcutaneous adipose tissues [49]. AnxA2 was also higher in
subcutaneous fat after weight loss achieved by a very low calorie diet [48]. In summary, the human
studies listed here do not consistently imply a common theme that associates similar changes of
AnxA2 levels in fat tissues upon weight loss. Likewise, discordant findings were also published on
the regulation of AnxA2 expression in murine obesity. Here, AnxA2 was expressed in epididymal
and mesenteric fat. Diet-induced obesity led to elevated AnxA2 protein levels in both fat depots,
which was also increased in the liver and skeletal muscle [59]. In spite of this, hepatic AnxA2 protein
amounts were found to be reduced in mice fed a high fat diet in a separate study [58]. Thus, for a
clearer picture of potential AnxA2 functions in fat tissue (Table 1), more studies are needed to improve
our understanding of the regulation of AnxA2 protein expression, localization and interaction partners
in adipocytes and other cells of fat tissues.
2.3. Annexin A6 (AnxA6)
AnxA6 is found in most cells and tissues, with abundant levels being expressed in endothelial and
endocrine cells, hepatocytes and macrophages [23,25–27,114]. The plasma membrane and endocytic
compartments represent the most common AnxA6 localizations [26,30,63,66,115–118], but AnxA6 is
also found along the secretory pathway [23,25,119], mitochondria [120] and lipid droplets [61,121].
Like other annexins, and depending on the cellular localization and repertoire of interaction partners,
AnxA6 participates in many cellular activities, some of which potentially relevant for adipose
tissue function, such as endo- and exocytosis, signal transduction, cholesterol homeostasis, stress
response [23,25–27,30,64,94,116] and lately, neutral lipid accumulation [61,62].
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The multifunctionality of AnxA6 has made it difficult to assign specific AnxA6 functions to
particular cell types, but despite a still limited number of studies addressing AnxA6 in adipocyte
biology, several cellular processes that are modulated by AnxA6 could possibly be relevant for adipocyte
function (Table 1). To begin with, AnxA6 upregulation inhibits cholesterol export from late endosomes,
which perturbs cellular cholesterol homeostasis similar to mutations in the late endosomal/lysosomal
NPC1 cholesterol transporter. This leads to reduced cholesterol levels in other compartments, such as
the plasma membrane, Golgi apparatus and recycling endosomes [63,73]. Consequently, membrane
trafficking is compromised, and we initially observed reduced numbers of caveolae due to caveolin-1
accumulation in the Golgi [63]. This could be highly relevant for adipocyte function, as caveolae are
most prominent in adipocytes, with roles in endocytosis, cholesterol and fatty acid uptake, lipid droplet
formation and signal transduction [122,123]. In follow-up studies, we then identified AnxA6-induced
cholesterol imbalance to cause mislocalization and dysfunction of several cholesterol-sensitive SNARE
proteins in the secretory pathway [72,73], all of which are fundamental for the metabolic response that
facilitates GLUT4 translocation in adipocytes [124]. Also, recent findings from our laboratories indicate
that cholesterol accumulation in late endosomes of NPC1 mutants promotes the interaction of AnxA6
with the Rab7-GTPase activating protein TBC1D15 (Rentero, Grewal and Enrich, unpublished results),
which has recently been implicated in Rab7-dependent pathways that regulate GLUT4 translocation
to the cell surface [125]. Impaired insulin signaling and glucose uptake in 3T3-L1 adipocytes upon
NPC1 inhibition [19] extend support for a model of upregulated AnxA6, through cellular cholesterol
imbalance, to impact on GLUT4 trafficking.
Secondly, AnxA6 associates with secretory granules in a Ca2+-dependent manner [67], participates
in Ca2+ homeostasis through store-operated Ca2+ entry [70] and alters catecholamine secretion [71],
all of which with links to the secretory pathway that enables adiponectin release [126]. Thirdly,
the scaffolding function of AnxA6 is critical for the formation and activity of several signalling
complexes [26,29,64–66], with roles in GLUT4 translocation and lipolysis [127]. Finally, we recently
identified the association of AnxA6 with lipid droplets in hepatocytes to influence their capacity to
store neutral lipids [61], which could also be relevant for neutral lipid storage in fat tissue.
Initial insights into AnxA6 functions in fat tissue were lately obtained from the characterization of
differentiated 3T3-L1 adipocytes overexpressing or lacking AnxA6. In this model, siRNA-mediated
AnxA6 knockdown impaired preadipocyte proliferation. Moreover, maturation of AnxA6-depleted
3T3-L1 adipocytes was associated with increased storage of triglycerides and elevated release of
adiponectin [68]. The latter finding was not observed in oleate-loaded cells [68], possibly indicating
independent mechanisms that cause changes in triglyceride accumulation and adiponectin release
upon AnxA6 depletion. Vice versa, AnxA6 overexpression in 3T3-L1 cells lowered cellular triglycerides
and adiponectin release (Figure 2). In addition, the catecholamine-stimulated phosphorylation of
hormone-sensitive lipase (HSL) to promote lipolysis was impaired in AnxA6-depleted cells and
coincided with AnxA6 localization on lipid droplets in adipocytes, implicating a scaffolding function
of AnxA6 at the lipid droplet membrane possibly relevant for HSL phosphorylation and not directly
linked to adiponectin release through the secretory pathway [68]. Importantly, this function of HSL is
not critical for fatty acid metabolism in non-adipose tissue [128], which might contribute to explain the
opposite effects of AnxA6 up- or downregulation on neutral lipid storage in cells from liver and fat
tissue [61,68]. Notably, AnxA6 levels did not change lipopolysaccharide response of 3T3-L1 adipocytes,
and basal as well as lipopolysaccharide-induced IL-6 levels were comparable in groups with high and
low AnxA6 levels [68].
Follow-up studies in AnxA6 KO-mice, which have normal body weight, glucose and insulin
levels, support some of the cell-based studies summarized above. In particular, serum adiponectin
levels were higher, while reduced amounts of adiponectin were found in the subcutaneous fat of the
AnxA6 KO-animals [68]. As cholesterol is critical for the release of adiponectin through the secretory
pathway [20], we speculate that the regulatory role of AnxA6 in cholesterol homeostasis [31,63,64,72,73]
could be responsible for alterations in adiponectin plasma levels in the AnxA6 KO-animals.
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Despite increased lipid storage in AnxA6-depeleted 3T3-L1 adipocytes, circulating triglycerides,
free fatty acids and cholesterol were normal in AnxA6 KO-mice [68]. Systemic lipid levels of
AnxA6-deficient animals were also comparable to controls after a high fat diet for 17 weeks [61,62].
Most interestingly, AnxA6 KO-mice gained less adipose tissue during high fat feeding [61,62], which
might be in line with the impaired proliferation observed in AnxA6-depleted preadipocytes [68].
On the other hand, and in contrast to the cell-based studies described above [68], circulating leptin and
adiponectin levels were slightly reduced in high fat diet fed AnxA6 KO-mice [61,62]. Lower fat mass is
usually associated with higher adiponectin and improved glucose homeostasis [21]. Such improvements
were not observed in the AnxA6 KO-animals [61,62] and AnxA6-related functions in other organs may
need to be considered to possibly explain these up till now opposing obervations.
Strikingly, AnxA6 deficiency in mice compromised regulatory steps to downregulate hepatic
gluconeogenesis that only became apparent after high fat diet feeding [61,62]. Likewise, dysfunctional
hepatic glucose homeostasis in AnxA6-KO mice was also observed after induction of metabolic stress
upon partial liver hepatectomy or starvation [129]. Given the prominent role for adipokines in the
coordination of hepatic glucose homeostasis, we speculate that so far unidentified changes in the
inter-organ metabolic communication beween fat and liver tissues of AnxA6-KO mice may contribute
to the fine-tuning of hepatic glucose metabolism, with potential consequences for the systemic control
of glucose in health and disease.
The abovementioned and in-part profound effects of AnxA6 up- or downregulation on the central
aspects of adipocyte function, including growth, lipid storage, and adiponectin release, suggest that
complex mechanisms might be in place to control AnxA6 expression levels in fat tissue. Several
studies provide some insight in this matter. AnxA6 protein expression modestly increased during
3T3-L1 cell adipogenesis and was clearly induced in mature human adipocytes when compared to their
respective preadipocytes [68]. AnxA6 protein levels were, however, not changed upon lipid loading of
adipocytes [68]. Likewise, exposure to high glucose or lipopolysaccharide did not impact on AnxA6
protein levels in 3T3-L1 cells. On the other hand, oxidative stress, which suppresses adiponectin
release and contributes to insulin resistance in obese adipose tissues [130], was associated with AnxA6
upregulation in 3T3-L1 adipocytes [68].
AnxA6 was also highly expressed in human monocytes, which can infiltrate fat tissue, and further
increased in monocytic cells of overweight patients [74]. How this might impact adipose tissue function
is still unclear, but high AnxA6 levels in phagocytes may accompany the process leading to foam cell
formation and atherosclerosis [64,74]. Alternatively, AnxA6-induced changes in membrane order at
the plasma membrane [131] may influence the distribution and activity of lipoprotein receptors and
cholesterol transporters at the cell surface responsible for cholesterol eﬄux [132]. Of note, adiponectin,
which protects from cardiovascular diseases [74,133], reduced AnxA6 protein expression in human
monocytic cells [74,133], but not in 3T3-L1 adipocytes [68].
Complex and differential AnxA6 expression patterns have also been observed in animal and
human studies. In subcutaneous, perirenal and epididymal adipose tissues from mice fed a high fat diet
for 14 weeks, AnxA6 levels were strongly induced [68]. This may in part be related to increased AnxA6
expression in macrophages [74]. Additionally, obese murine adipocytes also displayed higher AnxA6
protein levels [68]. AnxA6 protein amounts remained unchanged in the visceral fat of overweight
patients when compared to normal weight patients, illustrating that AnxA6 levels do not increase
when body weight and adipocyte size grow in humans [68]. Furthermore, AnxA6 expression was
induced in adipocytes during aging [35], which is associated with oxidative stress and a decline in
adipocyte function [134]. Hence, increased reactive oxygen species rather than cell hypertrophy seem
to mediate the upregulation of AnxA6 in adiposity.
Visceral fat accumulation has deleterious effects [2,68,69] and AnxA6 protein levels were higher
in human and murine visceral compared to subcutaneous adipose tissues [2,68,69]. In adipocytes
purified from the respective human fat depots, AnxA6 protein amounts were also more abundant
in the visceral fat cells [68]. Remarkably, fat depot distribution of AnxA6 changed in obesity. Here,
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AnxA6 levels were higher in subcutaneous adipose tissues compared to intraabdominal fat. Such a
change in fat depot expression is uncommon and cell-type specific regulation of AnxA6 may need to
be evaluated to identify the underlying mechanisms.
In murine epididymal fat, AnxA6 protein levels were approximately 60% higher in large when
compared to small adipocytes. This size-dependent change in AnxA6 expression was only detected
in insulin receptor knock-out mice but not in the respective control animals [47]. This indicates
that adipocyte growth is not associated with higher AnxA6 expression as long as the cells respond
to insulin [47]. Whether a differential insulin response of subcutaneous and visceral adipocytes [2]
contributes to altered AnxA6 protein needs further studies. Insulin did not change AnxA6 protein
levels in 3T3-L1 cells, excluding a direct effect of this hormone [68].
Finally, in brown fat, which is quite distinct from other fat tissues as its main function is to
produce heat, AnxA6 protein amounts remained unchanged in obesity [68]. Altogether, AnxA6 is
differentially expressed in the various fat depots and in some cases, response to diet was observed
(Table 1). Altogether this may indicate differential AnxA6 functions in the various fat tissues, which
still need to be resolved in future studies.
2.4. Other Annexins
2.4.1. Annexin A3 (AnxA3)
In comparison to the depth of literature on AnxA1, A2 and A6, up to date only a limited number
of studies have examined AnxA3 expression and function (Table 1). AnxA3 is most prominent in
neutrophils and macrophages and was detected in heart, lung, placenta, kidney and spleen, with highest
levels in murine adipose tissue [77]. Besides its Ca2+-dependent membrane binding behavior, its intra-
and extracellular locations and physiological functions are still poorly understood. Most AnxA3-related
studies focussed on its potential as a biomarker in several cancers and the association of AnxA3 with
chemotherapy resistance [135], with possible roles in the proliferative and invasive properties of cells.
Interestingly, a recent study identified the recruitment of AnxA3 to lipid droplets of hepatitis C virus
infected Huh7 hepatocytes [76], facilitating the interaction of viral proteins with apolipoprotein E
(ApoE) during virus maturation and egress. Given the prominent role of ApoE in mouse and human
adipocyte differentiation and lipid accumulation [136], one can speculate that yet to be identified
environmental signals may also trigger AnxA3-driven interactions with ApoE or other proteins on
the lipid droplet membrane during fat cell differentiation. In fact, one report identified AnxA3 to
negatively regulate adipogenesis. In this study, AnxA3 protein was highly expressed in preadipocytes
and strongly downregulated during 3T3-L1 cell differentiation [77]. Marked suppression of AnxA3
in early adipogenesis suggested an inhibitory function of AnxA3 in adipocyte differentiation [77].
Indeed, when AnxA3 was depleted by siRNA transfection of preadipocytes, expression of PPARγ2 and
lipid droplet accumulation were increased, enhancing terminal adipocyte differentiation [77]. Of note,
AnxA3 mRNA levels were comparable in the different white fat depots [77] (Table 2), indicating similar
roles in the various fat locations. Interestingly, stromal vascular cell fractions expressed higher AnxA3
mRNA levels compared to adipocytes [75]. Analysis of publicly accessible DNA microarray data
confirmed higher AnxA3 mRNA expression in murine stromal vascular cells (Table 2), suggesting that
AnxA3 might fulfill multiple cell-specific functions in fat tissue.
2.4.2. Annexin A5 (AnxA5)
AnxA5 is the most abundant annexin and except in neurons, is expressed ubiquitously [25,137].
During proliferation, differentiation and in many cancers, AnxA5 levels are often up- or
downregulated [138]. Ca2+ elevation triggers AnxA5 binding to various cellular sites [23,139,140] to
participate in cell growth and death, Ca2 signalling and homeostasis, membrane domain organization
and transport [23,30,140]. Therapeutically relevant, extracellular AnxA5 binds to outer membrane
phosphatidylserine, allowing detection of apoptotic cells [137]. Furthermore, AnxA5 has prominent
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extracellular roles in blood coagulation, phagocytosis, viral infection, membrane invagination and
membrane repair [137,138,141,142].
Although one can envisage several of these intra- and extracellular functions listed above being
relevant for the proper functioning of several cell types in adipose tissue, such as macrophages,
endothelial and vascular smooth muscle cells as well as adipocytes, current knowldege on AnxA5
function in fat physiology is still insignificant (Table 1). Analysis of publicly available expression
data (Geo profiles) revealed that AnxA5 mRNA was mostly expressed in murine adipocytes when
compared to the stromal vascular cells in subcutaneous and intraabdominal fat. Whereas adipocytes of
both fat depots had similar AnxA5 mRNA levels, stromal vascular cells in subcutaneous fat expressed
less AnxA5 mRNA (Table 2). In line with other differentiation models, AnxA5 protein expression
was induced in adipocytes during aging [35] and one study demonstrated an association of AnxA5
polymorphisms with obesity in a Korean patient cohort [78], which may suggest a function of AnxA5
directly or indirectly contributing to fat deposition, storage or mobilization.
2.4.3. Annexin A7 (AnxA7)
AnxA7 is the only annexin that contains a long (100 amino acids) and hydrophobic N-terminus.
Due to alternative splicing, a 47 kD splice variant is found in most tissues, while a larger 51 kDa
isoform is expressed in the brain, heart and skeletal muscle [143]. In these various cells and organs,
Ca2+-inducible association of AnxA7 with secretory vesicles, the plasma membrane and the nuclear
envelope has been observed [144], with possible roles in Ca2+/GTP-dependent exocytic pathways,
prostaglandin synthesis, cardiac remodelling and inflammatory myopathies [81,145,146]. In addition,
the GTPase activity of AnxA7 has potential as a tumour suppressor in several cancers [147].
The AnxA7 functions listed above and related to membrane transport, Ca2+ signalling and
hormone production could be relevant in fat, but very little is still known about potential roles for
AnxA7 in adipocytes or other cell types in this tissue (Table 1). Nevertheless, in other cells and tissues,
several AnxA7-related tasks may also influence adipose tissue function. For example, one mouse model
lacking AnxA7 displayed defects in Ca2+ release and Ca2+-dependent signal transduction, affecting
insulin secretion [82,83]. On the other hand, another independently generated AnxA7 KO-mouse model
was strikingly different and did not reveal a role for AnxA7 in Ca2+-dependent insulin secretion [79].
In addition, in some cell types, AnxA7 negatively regulates cyclooxygenase-dependent prostaglandin
E2 formation [80]. Hence, elevated plasma prostaglandin levels in AnxA7 KO-mice may contribute to
decreased glucose tolerance and elevated glucose-inducible insulin secretion [81]. Most relevant for fat
tissue in obesity, cyclooxygenase-dependent prostaglandin E2 production has been associated with
pathologic complications that lead to inflammation and fibrosis, impaired adaptive thermogenesis and
lipolysis in obese white adipose tissue [148].
Although the latter might indicate that AnxA7 plays a role in infiltrating immune cells in
dysfunctional adipose tissue, at present, very limited information on AnxA7 expression patterns in
normal and obese fat tissue is available. AnxA7 mRNA was comparable in adipocytes and stromal
vascular cells in subcutaneous and intraabdominal fat (Table 2). Evidently, more studies are needed to
possibly identify yet unknown AnxA7 functions in fat tissue.
2.4.4. Annexin A8 (AnxA8)
AnxA8 was first identified in human placenta [149] and, with the exception of acute promyelocyte
leukemia [150], is only expressed at low levels in lung, skin, liver, and kidney [151]. Earlier reports
described AnxA8 to inhibit blood coagulation [152], but cellular AnxA8 localizations and functions are
still not fully understood. AnxA8 may provide opportunities as a biomarker in several cancers [153–155]
and more recently, has been linked to the transdifferentiation of retinal pigment epithelial cells [156].
Nonetheless, within the context of adipose tissue function, the unique affinity of AnxA8 towards
phosphatidylinositides and F-actin relevant for membrane-cytoskeleton interactions, might be most
important. In fact, these distinctive membrane- and actin-binding properties of AnxA8 affect
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the functioning of late endosomes [84,85] and in endothelial cells, this contributes to control the
delivery of CD63 from late endocytic vesicles to the cell surface for leukocyte recruitment and
migration [86,89]. In addition, AnxA8 is associated with cholesterol-rich late endosomes, and similarly
to AnxA6 overexpression or NPC1 inhibition [19,31,63,64,72,73], AnxA8 depletion results in cholesterol
accumulation in this compartment [87]. This may indicate a coordinated mechanism to control AnxA8
and AnxA6 expression levels and their relative amounts in the late endosomal compartment. Along
these lines, and as discussed for AnxA6 overexpression and NPC1 deficiency above (see 2.3.), it is
tempting to speculate that late endosomal cholesterol accumulation triggered by AnxA8 downregulation
might compromise adipocyte function leading to the improper performance of molecular events in
caveolae [63,122,123], or related to insulin signaling and GLUT4 translocation [19,72,73,124].
The findings described above suggest that changes in AnxA8 expression levels may cause cellular
dysfunction However, little is so far known if AnxA8 expression levels correlate with metabolic
complications in obese fat tissue (Table 1). AnxA8 mRNA was expressed in human adipose tissues and
was similar in subcutaneous and visceral fat depots of obese men [88]. In mice, AnxA8 mRNA levels
were higher in adipocytes than stromal vascular cells. Interestingly, AnxA8 expression in adipocytes
was more abundant in subcutanoues fat depots (Table 2). This observation adds AnxA8 to the list of
candidate proteins that are differentially expressed in the various fat depots, and possibly relevant to
further evaluate the deleterious effects of visceral adiposity [88].
2.4.5. Other Annexins
Up to date, it is unknown if the remaining annexins AnxA4, A9, A10, A11 and A13 contribute
to the proper functioning of adipose tissue (Table 1). Out of those annexins, current literature has
associated AnxA4 with cAMP production, which could be relevant for lipolysis [90]. Also, roles for
AnxA11 in exocytosis and cytokinesis could influence fatty acid release or adipokine secretion [91].
Of note, expression data for AnxA4, AnxA9 and AnxA13 in fat was not publicly available, but AnxA10
and A11 are indeed expressed in fat tissue. AnxA10 expression was similar in adipocytes and stromal
vascular cells in subcutaneous and intraabdominal fat (Table 2). AnxA11 was mostly expressed in the
stromal vascular cells of subcutaneous adipose tissues when compared to the respective adipocytes and
to intraabdominal stromal vascular cells (Table 2). Differential levels of AnxA11 mRNA between the
cell populations did not exist in intraabdominal adipose tissue (Table 2). Further studies are evidently
required to unravel their possible functions in fat tissue.
Table 2. Expression of annexins AnxA3, A5, A7, A8, A10 and A11 mRNA in murine adipose tissues.
Analysis of publicly accessible DNA microarray data (Geo Profiles; DataSet Record GDS2818) was
done with unpaired Students t-test. A p-value < 0.05 was regarded as significant.
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functioning of late endosomes [84,85] and in endothelial cells, this contributes to control the delivery 
of CD63 from late endocytic vesicles to the cell surface for leukocyte recruitment and migration 
[86,89]. In addition, AnxA8 is associated with cholesterol-rich late endosomes, and similarly to 
A xA6 overexpressio  or NPC1 inhibition [19,31,63,64,72,73], AnxA8 depletion results in cholesterol 
accumulation in this compartment [87]. This may indicate a coordinated mechanism to control 
A xA8 and AnxA6 expression levels and their relative amounts in the late endosomal compartment. 
Along these lines, and as discussed for A xA6 overexpressi  and NPC1 deficiency above (see 2.3.), 
it is te pting to speculate that late endosomal ch lesterol accumulation triggered by AnxA8 
downregulation might compromise adipocyte function leading to the improper performance of 
molecular events in caveolae [63,122,123], or related to insulin signaling and GLUT4 translocation 
[19,72,73,124]. 
The findings described above suggest that changes in AnxA8 expression levels may cause 
cellular dysfunction However, little is so far know  if AnxA8 expression levels correlate with 
metabolic complications in obese fat tissue (Table 1). AnxA8 mRNA was expressed in human adipose 
tissues and was similar in subcutaneous and visceral fat depots of obese men [88]. In mice, AnxA8 
mRNA levels were higher in adi ocytes tha  stromal vascular cells. Interestingly, AnxA8 expression 
in adipocytes was more abundant in subcutanoues fat depots (Table 2). This observation adds AnxA8 
to the list of candidate proteins that are differentially expressed in the various fat depots, and possibly 
relevant to further evaluate the deleterious effects of visceral adiposity [88]. 
2.4.5. Oth r Annexins
Up to date, it is unknown if the remaining annexins AnxA4, A9, A10, A11 and A13 contribute to 
the proper functioning of adipose tissue (Table 1). Out of those annexins, current literature has 
associated AnxA4 with cAMP production, which could be relevant for lipolysis [90]. Also, roles for 
AnxA11 in exocytosis and cytokinesis could influence fatty acid release or adipokine secretion [91]. 
Of note, expression data for AnxA4, AnxA9 and A xA13 in fat was not publicly available, but 
AnxA10 and A11 are indeed expressed in fat tissue. AnxA10 expression was similar in adipocytes 
and stromal vascular cells in subcutaneous a d intraabdominal fat (Table 2). AnxA11 was mostly 
expressed i  the stromal vascular cells of subcutaneous adipose tissues when compared to the 
respective adipocytes and to intraab omi al stro al vascular cells (Table 2). Differential levels of 
AnxA11 mRNA betwe n the cell pop latio s did not exist in intraabdominal adipose tissue (Table 
2). Further st dies are evidently req ired to unravel the r possible functions in f t tissue. 
Table 2. Expression of a nexins AnxA3, A5, A7, A8, A10 and A11 mRNA i  murine adipose tissues. 
Analysis of publicly accessible DNA microarray dat  (Geo Pro iles; D t Set Record GDS2818) was 
done with unpaired Students t-test. A p-value < 0.05 was regarded as significant. ,  and ↔ indicate 
higher, lower a d unchanged mRNA levels, respectively, in adipocytes relativ  to stromal vascular 
ells (SVC) or in subcutaneous (sc) fat compared to intraabdominal (intra) fat. The mRNA expression 
ata for AnxA4, nxA9 and A xA13 in f t tissue were no  available. 
 Subcutaneous Fat 
Adipocyte/SVC 
Intrabdominal Fat 
Adipocyte/SVC 
Adipocytes 
Sc/Intra 
SVC 
Sc/Intra 
AnxA3   ↔ ↔ 
AnxA5   ↔  
AnxA7 ↔ ↔ ↔ ↔ 
AnxA8     
AnxA10 ↔ ↔ ↔ ↔ 
AnxA11  ↔ ↔  
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important. In fact, these distinctive membrane- a d actin-binding properties of AnxA8 affect the 
functioning of late endosomes [84,85] and in endothelial cells, this ibut s to control the delivery 
of CD63 from late endocytic vesicles to the cell surfac for leukocyte recru tment and migration 
[86,89]. I  add tion, AnxA8 is associated with cholest rol-rich late endosomes, and similarly to 
AnxA6 overexpression or NPC1 inhibition [19,31,63,64,72,73], A xA8 depletion results in cholesterol 
accumulation in this compartment [87]. This ay indicate a co rdinated mechanism to control 
AnxA8 an  AnxA6 xpression levels and their relative amounts in the ate endosomal compartment. 
Along these line , and as discussed for AnxA6 verexpression and NPC1 d fici ncy above (see 2.3.), 
it is tempting to speculate t at late endoso al holester l accumulation triggered by AnxA8 
downregulation ight compromise adipocyte function leading to th  improp r performance of 
molecular events in caveolae [63,122,123], or related to insulin signaling d GLUT4 translocation 
[19,72,73,124]. 
The findings d scribed above suggest that chang s in AnxA8 expression levels may cause 
cellular dysfunction H wever, little is s  far known if AnxA8 expression levels correlate with 
met b lic complication  in obese fat tissue (Table 1). AnxA8 mRNA was expressed in human adipose 
tis ues nd was similar in subcutaneous and visceral fat depots of obese m n [88]. In mice, AnxA8 
mRNA levels were higher in adip cytes than stromal vascular ce ls. Interestingly, AnxA8 expression 
in adipocytes was more ab n a t in subcutan ues fat depot (Table 2). This observation adds AnxA8 
to the list of ca did e proteins that are diff rentially expressed i  th  various fat depots, and possibly 
relevant to further valuate the deleterious effects of visceral adiposity [88]. 
2.4.5. Other Annexins 
Up to date, t is unknown if the remaini g annexins AnxA4, A9, 0, A11 and A13 contribute to 
the proper functi ning of adipose tissue (Table 1). Out of those a nexins, current literature has 
associa ed nxA4 with cAMP production, which could be re evant for lipolysis [90]. Also, roles for 
AnxA11 i  exocytosis and cytokinesis could influenc  fatty acid release or adipokine secretion [91]. 
Of note, expressio  data for A xA4, AnxA9 and AnxA13 in fat was not publicly available, but 
AnxA10 a d A11 are in eed expressed i  fat tissue. AnxA10 expression was similar in adipocytes 
nd st omal vasc lar cells in subcutaneous and intraabdominal fat (Table 2). AnxA11 was mostly 
expressed in the st omal vasc lar cells of subcutaneous adipose tissues when compared to the 
respective adi ocytes a d to intraabdominal st omal vascular cells (Table 2). Differential levels of 
nxA11 mRNA betwe n th  c ll popul tions did n t exist  intr abdominal adipose tissue (Table 
2). Fu ther stud es are evi en ly equired to unrav l their po s ble functions in fat tissue. 
Table 2. Expressi  of nnexins nx 3, A5, A7, A8, A10 and A11 mRNA in murine adi ose tissues. 
Analy s of publicly accessible DNA cr ar a  data (Geo Profiles; DataSet Record GDS2818) was 
done with unpaired Students t-test. A p-value < 0.05 was reg rded as significa t. ,  and ↔ indicate 
higher, low r and uncha ged mRNA lev ls, es ect v ly, in adip cytes re ative to stromal vascular 
cells (SVC) or in subcutaneous (sc) fat compared to intra bdominal (intra) fat. The mRNA expression 
dat  for Anx 4, nxA9 an  AnxA13 in f  tissue were not available. 
 Subcutaneous Fat 
Adipocyte/SVC 
In rabdominal Fat 
Adipocyte/SVC 
Adipocytes 
Sc/Intra 
SVC 
Sc/Intra 
AnxA3   ↔ ↔ 
AnxA5   ↔  
AnxA7 ↔ ↔ ↔ ↔ 
AnxA8     
AnxA10 ↔ ↔ ↔ ↔ 
AnxA11  ↔ ↔  
AnxA5
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important. In fact, these distinctive membrane- and actin-binding properties of AnxA8 affect the 
functioning of late endosomes [84,85] and in endothelial cells, this contributes to control the delivery 
of CD63 from late endocytic vesicles to the cell surface for leukocyte recruitment and migration 
[86,89]. In additi n, AnxA8 is associated with cholesterol-rich late endos mes, and similarly to 
AnxA6 overexpression or NPC1 inhibition [19,31,63,64,72,73], AnxA8 d pl tion results in cholesterol 
accumulation in this compartment [87]. This may indicate a coordinat d mechanism to control 
AnxA8 and AnxA6 expression levels and their relative amounts in the late endosomal compartment. 
Alo g these lines, and as discussed for AnxA6 overexpression and NPC1 deficiency above (see 2.3.), 
it is tempting to speculate that late endosomal cholester l accumulation triggered by AnxA8 
downregulation might compr mise adipocyte function leading to the improper performance of 
molecular events in caveolae [63,122,123], or related to insulin signaling and GLUT4 translocation 
[19,72,73,124]. 
The findings described above suggest that changes in AnxA8 expression levels may cause 
cellular dysfunction However, little is so far known if AnxA8 expression levels correlate with 
metabolic complications in obese fat tissue (Table 1). AnxA8 mRNA was expressed in human adipose 
tissues and was similar in subcutaneous and visceral fat depots of obese men [88]. In mice, AnxA8 
mRNA levels were higher in adipocytes than stromal vascul r cells. Interesti gly, nxA8 expression 
in adipocytes was more abundant in subcuta oues fat depots (Table 2). This observation adds nx 8
to the list of candidate proteins that are differentially expressed in the various fat depots, a d possibly 
releva t to further evaluate the deleterious effects of visceral adip ty [88]. 
2.4.5. Other Annexins 
Up to date, it is unknown if the remaining annexins AnxA4, A9, 10, A11 and A13 contribute to 
the proper functio ing of adipose tissue (Table 1). Out of those annexins, current li rature has 
associated A xA4 with cAMP production, which could be relevant fo  lipolysis [90]. Also, roles for 
nxA11 in exocytosis and ytokinesis could influ nce fatty acid release or adipokin  secretion [91]. 
Of note, expression data for AnxA4, A xA9 and AnxA13 in f t was ot publ cly available, but 
AnxA10 and A11 are indeed expressed in fat tissue. A xA10 expression was similar in adipocytes 
and stromal vascular cells in subcutaneous and i tra bdomin l f t (Table 2). AnxA11 was mostly 
expre sed in the tromal v scular cel s of subcutan ous adipose ti sues when compared to th  
respective adipo y es and to intraabdominal stro al vascular cells (Table 2). Diff renti l levels of 
AnxA11 mRNA between the cell populat ons did not xist in intraabdomi al adipose is ue (Table 
2). Further s udies are evidently required to unrav l their possible functions in fat t ssue. 
Table 2. Expression of annexins AnxA3, A5, A7, A8, A10 a d A11 mRNA in murine adipose tissues. 
Analysis of publicly accessible DNA microarray data (Geo Profiles; DataSet Record GDS2818) was 
done with unpa red Students t-test. A p-v lue < 0.05 wa  reg rded as significant. ,  and ↔ indicate 
higher, lower and unchanged mRNA level , respectively, i  adipocytes relative to stromal vascular 
cells (SVC) or in subcutaneous ( c) fat compared to intraabdominal (intra) fat. The mRNA expression 
data for AnxA4, AnxA9 nd AnxA13 in fat tissue were not available. 
 Subcutaneous Fat 
Adipocyte/SVC 
Intrabdominal Fat 
Adipocyte/SVC 
Adipocytes 
Sc/Intra 
SVC 
Sc/Intra 
AnxA3   ↔ ↔ 
x 5   ↔  
AnxA7 ↔ ↔ ↔ ↔ 
AnxA8     
AnxA10 ↔ ↔ ↔ ↔ 
AnxA11  ↔ ↔  
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important. In fact, these distinctive membra e- and actin-binding prop r ies of AnxA8 affect the 
functioning of late endosomes [84,85] and in endothelial cells, this contributes to control the delivery 
of CD63 from late endocytic vesicl s to the cell su face for leukocyte recruitment and migration 
[86,89]. In additio , AnxA8 is as ociated with cholesterol-rich lat  endosomes, and similarly to 
A xA6 overexpression or NPC1 inhibition [19,31,63,64,72,73], AnxA8 depletion results in cholesterol 
ac u ulation in this compartme t [87]. This may in icate a coordinated mechanism to control 
AnxA8 a d AnxA6 expression levels an  their relative am unts in the late endosomal compartment. 
Along these lines, a  as discussed for xA6 overexpression and NPC1 deficiency above (see 2.3.), 
it is tempting to speculate that late endosomal cholesterol accumulation triggered by AnxA8 
dow regulation might comprom se adipocyte funct on leading to the improper performance of 
mol cular events in caveolae [63,122,123], or rel ted to insulin sign ling and GLUT4 translocation 
[19,72,73,124]. 
The findi g  described above suggest that change  i AnxA8 expression levels may cause 
cellular dysfunctio  However, little is so far known if AnxA8 expression levels correlate with 
metabolic complications in obese fat tissue (Table 1). AnxA8 RNA w s expres d in human adipose 
tissues and w s si il r in subcutaneous and visceral fat depots of obese men [88]. In mice, AnxA8 
mRNA levels wer  higher in adipocytes than stromal vascular cells. Interestingly, AnxA8 expression 
in adipocytes was more abundan  in subcut n ues fat depots (Table 2). This observation adds AnxA8 
o the list of c ndidate p ote n  that are differentially expressed in the variou  fat depots, and possibly 
relevant to furth  evaluat  he delet ious effects of visceral adiposity [88]. 
2.4.5. Other Annexins 
Up to date, it is u k own if the remaining annexins AnxA4, A9, A10, A11 and A13 contribute to 
the proper func o ing of adipose tissue (Table 1). Out of those annexins, current literature has 
ass iated AnxA4 with cAMP pro uction, which could be elevant f r lipolysis [90]. Also, roles for 
AnxA11 in exocytosis and cytokinesis coul influence f tty ac d release r adipokine secretion [91]. 
Of note, expression data for AnxA4, AnxA9 and AnxA13 in fat was not p blicly available, but 
AnxA10 and A11 are indeed expressed in fat ti ue. AnxA10 expression was imilar in adipocytes 
and s romal vascular cells in subcutaneous and intraabdominal fat (Table 2). AnxA11 was mostly 
expressed in the stromal vascular cells of ubcu n ous adip se tissues w en compared to the 
respective adipocyt  and o intr ab ominal tromal vascular ells (Table 2). Differential levels of 
AnxA11 mRNA betwee  the ce l populatio s did not exist in intr abdominal adipose tissue (Table 
2). Further studies are evidently required to unravel their possibl  functions in fat tissue. 
Tabl  2. Expression of annexins AnxA3, A5, A7, A8, A10 and A11 mRNA in murine adipose tissues. 
Analysis of publicly ccessible DNA microarray d ta (G o Profiles; DataSet Record GDS2818) was 
done with unpaired Students t-t st. A p-value < 0.05 w s regarded as significant. ,  and ↔ indicate 
igher, lower and unchang d mRNA levels, respectively, adipocytes relative to stromal vascular 
cells (SVC) or in subcutane us (sc) fat compar d to intra bdomin l (intra) fat. The mRNA expression 
data for AnxA4, AnxA9 and AnxA13 in  tissue were not available. 
 Subcut ne us F t
Adipocyte/SVC 
Intrabdominal Fat 
Adipocyte/SVC 
Adipocytes 
Sc/Intra 
SVC 
Sc/Intra 
AnxA3   ↔ ↔ 
AnxA5   ↔  
AnxA7 ↔ ↔ ↔ ↔ 
AnxA8     
AnxA10 ↔ ↔ ↔ ↔ 
AnxA11  ↔ ↔  
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important. In ct, these distinctive me bra e- and ctin-binding properties of AnxA8 aff ct the
functioning of late endosomes [84,85] and in endotheli l cells, this con ributes to co rol the delivery
of CD63 from late endocytic vesicles to the cell surfac  for leuk cy  rec uitment and gratio
[86,89]. In addition, AnxA8 is assoc ated with cholesterol-rich late endos mes, and similarly to
AnxA6 overexpress on r NPC1 inhibition [19,31,63,64,72,73], AnxA8 epl tion results in chol ste
accumulation in this compartment [87]. This m y indicate a coordinated mec anism to control
nxA8 and A xA6 expression levels n  their relative amounts in the late e dosomal c mpartment.
Along these lines, and as discussed for A xA6 over xpr si n and NPC1 deficiency above (see 2.3.),
it is tempting to sp c e that la e endoso al h lest rol ac u ulation trigger d by AnxA8
downregulation might c promise adipocyte functi n leading to the improper performance of
molecular events in caveolae [63,122,123], or related to insulin signaling and GLUT4 translocation 
[19,72,73,124]. 
The findi gs described ab ve suggest tha  changes in AnxA8 expression level  m y cau e
cellular dysfunction However, little is so far know  if AnxA8 expr ssion l vels correlat  wit
metabolic complicat ons i  obe e f t tissue (Table 1). AnxA8 mRNA w s ex r ssed in hu an adipose
tissues and was similar in ubcutaneous and vis eral f t depots of obese men [88]. In mice, AnxA8
mRNA level ere higher in adip cytes t an strom l vascular cells. Intere tingly, nxA8 expression
in adipocytes was more abundant in subcutanoues fat depots (Table 2). This observation d s AnxA8
to the list f candi ate pro ins that re differ ntially expr ssed in the various fat depots, and possibly 
relevant to further evaluate the deleterious effects of visceral adiposity [88]. 
2.4.5. Oth r Ann xins 
Up to date, it is unknow  if the remaining annexins AnxA4, 9, 10, A11 and A13 contribut  to
the proper functioning of adi ose tissue (Table 1). Out of t ose annexins, current literatur  has
associated AnxA4 with cAMP producti n, which could be releva t for lipolysis [90]. Also, r les for
AnxA11 in exocyt sis nd cytokinesis could influence fatty acid release or adipokine secretion [91].
Of note, expression data for AnxA4, A xA9 and AnxA13 in fat was not public y available, but
AnxA10 and A11 are indeed express d in fat tissue. nxA10 exp ession was similar in adipocy es
and stromal vascular cel s in s bcutaneous a d intraabdominal fat (Table 2). AnxA11 w s mostly
expr ssed in the s romal va cul r cells of subcutaneous adipose tissues wh n o par d to the
respective adipocy e  a d to intra bdom nal stro al vascula  cells (T ble 2). Diff ren l l v ls f
AnxA11 mRNA bet e n the c ll populati n  id not xist in intraabdominal ad po e tissue (Table 
2). Further studies are evidently required to unravel thei  possible fu ctions in fat tissu . 
Table 2. Expressi n of annexins nxA3, 5, 7, A8, A10 nd A11 mRN  n murine adipos  tissues. 
Analysis of publicly accessible DN  microarray data (G o Profile ; DataSet R cord GDS2818) was 
d ne with unpaired Students t-test.  p- alue < 0.05 was regarded s significant. ,  and ↔ indicate 
higher, lower and unchanged mRNA lev ls, re pectivel , in a ipocytes relative to stromal vascular 
cells (SVC) or in subcutaneous (sc) fat compared to intraabdominal (intra) f t. The mRNA expression 
data for AnxA4, A xA9 and AnxA13 in fat tissue were not available. 
 Subcutaneous Fat 
Adipocyte/SVC 
I trabdominal Fat 
Adipocyte/SVC 
Adipocytes 
Sc/Intra 
SVC 
Sc/Intra 
AnxA3   ↔ ↔ 
AnxA5   ↔  
AnxA7 ↔ ↔ ↔ ↔ 
AnxA8     
AnxA10 ↔ ↔ ↔ ↔ 
AnxA11  ↔ ↔  
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impor ant. In fact, t ese distinct ve m mbrane- and acti -binding pro erties of AnxA8 aff ct the 
fun tio ing of late dosomes [84,85] and in nd theli l cells, this ontributes to ontrol the delivery 
of CD63 f om t  cytic v sicle  to t  cell urface for euk cyte recruitment and migration 
[86 89]. In a dition, AnxA8 i  associated with cho esterol-rich late endosom , and similarly to 
AnxA6 overexpression or NPC1 i hibit  [19,31,63,64,72,73], AnxA8 depletion esults in cholesterol 
accu ulati n i  thi  co r e t [87]. This may indicate a coo dinated me h ism t  contr l 
AnxA8 nd nxA6 expr ss  levels and th ir relative amo nts in the late e somal compartment. 
Along h se lines, and s dis uss d for AnxA6 overexp essio  a d NPC1 deficiency above (see 2.3.), 
it  t mpt t  spe la  that late endosomal chol te ol accumulation trigger d by AnxA8 
downregulation m ght compromise dipoc te function leading to th  i roper performance of 
olec lar event  in caveola  [63,122,123], or relat d to insuli  ignaling and GLUT4 translocation 
[19,72,73,124]. 
The fi dings d cribed above sugge t that chang s in AnxA8 xpr ssion levels may cause 
cellular dysfunction However, little is so far known if AnxA8 expressi n le els correlate with 
met b lic complications in obese f t tissu  (Table 1). A xA8 mRNA was expressed in human adipose 
tissu s and wa  si il r  subcutaneous and visceral fat de ots of obese men [88]. In mice, AnxA8 
mRNA levels were high r in adip cytes t a  strom l vascular cells. Interestingly, AnxA8 expression 
i  adipocyt s was more abun ant in subcutanoues fat depots (Table 2). This observation adds AnxA8 
to the list of cand date proteins that are differentially expressed in the various fat depots, and possibly 
relevant to further evaluate the deleterious effects of visceral adiposity [88]. 
2.4.5. Other Annexins 
Up to at , it is unkn wn if th remaining nexi s xA4, A9, A10, A11 a d A13 contribute to 
t  p op r fu cti ning of adipos  tissue (Tabl 1). Out f tho e annexins, c rrent literature ha  
soc ated AnxA4 with cAMP prod tio , which could be r levant for lipolysis [90]. Also, roles for 
AnxA1  i  exocytosis a d cytokinesis cou d influence fatty cid relea e or adipokin  secretion [91]. 
Of note, xpression d ta f r nx 4, A xA9 and AnxA13 in fa  was not publicly available, but 
0 and A11 are indeed expressed in fat tissue. AnxA10 expressi  was similar in adipocytes 
d stromal v scular cells i  subcutan ou a d intraab minal fat (Table 2). AnxA11 was mostly 
expressed i  the stromal vascular cel s of subcutan ous adipo e tissues when compared to the 
res ectiv dipocytes a d to intr abdominal stro al vascular cells (Table 2). Differential levels of 
AnxA11 mRNA betwee  he cell populatio s did  exist in intraabd minal ipose tissue (Table 
2). Furth r studies are evide tly r quired to unrav l their possible functions in fat tissue. 
Ta le 2. Ex es ion of nexins nxA3, A5, A7, A8, A10 and A11 in murine adipose tis ues. 
An lysis of publicly a cessibl  DNA mi roarray data (Geo Profiles; DataSet Record GDS2818) was 
do e with unpai d Studen s t-test. A p-v lue < 0.05 was regarded as significant. ,  and ↔ indicate 
higher, lower and unc anged mRNA levels, respectively, in adipocytes relative to stromal vascular 
cells (SVC) or in subcutaneous (sc) fat compared to intra bdominal (i tra) fat. The mRNA expression 
data for AnxA4, Anx 9 and nxA13 in fat tissue were not available. 
 Subcutaneous Fat 
Adipocyte/SVC 
bdominal Fat 
Adipocyte/SVC 
Adipocytes 
Sc/Intra 
SVC 
Sc/Intra 
AnxA3   ↔ ↔ 
AnxA5     
AnxA7 ↔   ↔ 
AnxA8     
AnxA10 ↔ ↔ ↔ ↔ 
AnxA11  ↔ ↔  
AnxA7
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important. In fact, these distinctive membrane- and acti -binding properties of AnxA8 ff ct th  
functioning of late endosomes [84,85] and in end thelial cells, this contributes to contr l the d li ery 
of CD63 from late endocytic vesicles to the cell surface f r leukocyte recruitment and migration 
[86,89]. In addition, AnxA8 is associated with chol terol-rich late end s mes, an  similarly to 
AnxA6 overexpression or NPC1 inhibition [19,31,63,64,72,73], AnxA8 d pletion r sults in cholesterol
accumulation in this compartment [87]. This may indicat  a coordi ated mechanism to control 
AnxA8 and AnxA6 expression levels and their r lative mounts in t e late endos mal com artme t. 
Along these lines, and as discussed for A xA6 overexpression and NPC1 deficiency above (s e 2.3.), 
it is tempting to speculate that late endoso al cholesterol ccu ulation trigg red by AnxA8 
downregulation might compromise adipocyte fu ctio  leading to the improper performa ce of 
molecular events in caveolae [63,122, 23], or related to insuli  signaling and GLUT4 translocation 
[19,72,73,124]. 
The findings described above suggest that changes in AnxA8 expressi n l vels may c us  
cellular dysfunction However, little is so far know  if AnxA8 expressio  levels rrel te with 
metabolic complications in obese fat tissue (Tabl  1). Anx 8 mRNA was expresse  in human adipose 
tissues and was similar in subcutaneous and isceral fat d pots of obese men [88]. In mice, A xA8 
mRNA levels were higher in adipocytes than stromal vasc lar c lls. Interestingly, AnxA8 r ssion 
in adipocytes was more abundant in subcutanoues fat epots (Table 2). This obs va i  adds AnxA8 
to the list of candidate proteins that are differentially expressed in t  various fat depo , and possibly 
relevant to further evaluate the deleterious effects of visce al adiposi y [88]. 
2.4.5. Other Annexins 
Up to date, it is unknown if the remaining exins AnxA4, A9, A10, A11 and A13 c ntri ute o 
the proper functioning of adipose ti ue (Tabl  1). Out of t ose an xi s, urrent literat r  has 
associated AnxA4 with cAMP production, which could b r levant f r lipolysis [ 0]. lso, roles for 
AnxA11 in exocytosis and cytokinesis could influence fatty cid eleas  or adipokine secretion [91].
Of note, expression data for AnxA4, AnxA9 nd AnxA13 in fat was not p blicly avail le, but 
AnxA10 and A11 are indeed expressed in fat tissu . AnxA10 xpr ssion was similar i  adipocytes 
and stromal vascular cells in subcutaneous and intraabd inal fat (T l  2). A xA11 was mostly 
expressed in the stromal vascular cells of subcuta eou dipose tissu s w  compa ed to the 
respective adipocytes and to intraabdominal stromal v scular c lls (Table 2). Differe tial l vels of 
AnxA11 mRNA between the cell populations did not exist in intraabdo i al adipose tissue (Table 
2). Further studies are evidently required to unravel their possible functions in fat tissue. 
Table 2. Expression of annexins AnxA3, 5, A7, A8, A10 and A11 mRNA in murine dipose tissues. 
Analysis of publicly accessible DNA microarray data (Geo Profil s; DataSet Record GDS2818) was 
done with unpaired Students t-test. A p-value < 0.05 was regarded as significant. ,  and ↔ indicate 
higher, lower and unchanged mRNA levels, respectively, in adip cytes relative to stromal vascular 
cells (SVC) or in subcutaneous (sc) fat compared to intraabdomin l (i tra) fat. The mRNA expr ssion 
data for AnxA4, AnxA9 and AnxA13 in fat tissue were not available. 
 Subcuta eous Fat 
Adipocyte/SVC 
Intrabdominal Fat 
A ipocyte/SVC 
Adipocytes 
Sc/Intra 
SVC 
Sc/Intra 
AnxA3   ↔ ↔ 
AnxA5   ↔  
AnxA7 ↔ ↔ ↔ ↔ 
AnxA8     
AnxA10 ↔ ↔ ↔ ↔ 
AnxA11  ↔ ↔  
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 14 of 22 
 
important. In fact, these distinc iv  membra e- and ctin-binding pr per ies of AnxA8 aff ct the 
functioning of late endosomes [84,85] and in endothelial cells, this o tributes to ontrol th  deliv ry 
of CD63 from late endocytic ves cl s to the cell s face for leukocyt  r cruitment and migration 
[86,89]. In additio , AnxA8 is as ociated with cholester l-rich l te endosomes, a  simil rly to 
A xA6 overexpression or NPC1 i hibiti n [19,31, 3,64,72,73], AnxA8 depletio  results  cholest rol 
ac u ulation in this compartme t [87]. This m y in icate a coordinated mechanism t  co trol 
AnxA8 a d Anx 6 expressio  l vels a  their relative am unts in th  lat  endosomal compartme t. 
Along these lines, and as discussed for A xA6 overexpression and NPC1 deficien y above (see 2.3.), 
it is tempting to speculat  that late endosomal h lesterol acc mulation tri ered by nxA8
downregulation ight comprom se adip cyte funct on leading o the improper performance of 
mol cular events in cav olae [63,122,123], or rel ted to insulin sign li g and GLUT4 translocation 
[19,72,73,124]. 
The finding  desc ibed above suggest that cha ge  i AnxA8 e pression levels may cause 
cellular dysfunction However, ttle is so f r known if AnxA8 xpression le els correlate with 
metabolic complications i  obese fat t ssu  (Ta le 1). AnxA8 mRNA w s expres d in human adipose 
tissues and w s simil r in subcut ne us a d vi ceral f t depots of obese men [88]. I  mice, AnxA8 
mRNA levels wer  higher in adi ocyt s tha  stromal vas l r cell . Inter sti gly, An A8 expre sion 
in adipocytes was more abundan  in subcut noues fat depots (Tabl 2). This observation adds AnxA8 
o the list of c ndidate p o e ns at are differentially expres ed in he variou  fat depots, and possibly 
relevant to furth  evaluat  he delet ious effects o  visceral adiposity [88]. 
2.4.5. Other Annexins 
Up to date, it is u k ow  if the remaini g nn xins nxA4, A9, A10, A11 and A13 co tribute to 
the proper func oning of adipose tissue (Table 1). Out of t os  annexins, rrent literature has 
asso iated AnxA4 with cAMP pro uctio , which could be relevant f r lipolysis [90]. Als , roles for 
AnxA11 in exocytosis and cytoki esis coul influe ce f tty ac d rel ase r d pokine secretion [91]. 
Of note, expressio  data for xA4, xA9 and Anx 13 in fat w s ot p blicly vailable, but 
AnxA10 and A11 are indeed expresse  i  fat ti ue. AnxA10 expr sion w s imilar in adipocytes 
and stromal vascula  ells i  sub utaneous nd intr ab omi al fa  (Tab 2). nxA11 was mostly 
expressed in the stromal vascular cells of sub ut n us dip e tissues w e  comp re  to the 
respective adipocytes and o intraabdo inal stromal ascul r c lls (Table 2). Differ ntial le e s of 
AnxA11 mRNA betwee  the cell populat o s did ot exis  in intraabdominal adipose tissue (Tabl  
2). Further studies are evidently required to u ravel their possible functions in fat tissue. 
Tabl  2. Expression of annexins AnxA3, A5, A7, A8, A10 and A11 mRNA in murine adipose tissues. 
Analysis of publicly ccessible DNA microarray d ta (G o Profiles; DataSet Record GDS2818) was 
done with unpaired Stude ts t-te t. A p-value < 0.05 w s r garded as significant. ,  and ↔ i icate 
igher, lower and unchang d mRNA levels, respectively, in adipocytes relative to stromal vascular 
cells (SVC) or in subcutane us (sc) fat compared to intraab ominal (intra) fat. The mRNA expression 
data for AnxA4, AnxA9 and nxA13 in fat tissue were not available. 
 Subcut n us F t
Adipocyte/SVC 
Intrabdominal Fat 
Adipocyte/SVC 
Adipocytes 
Sc/Intra 
SVC 
Sc/Intra 
AnxA3   ↔ ↔ 
AnxA5   ↔  
AnxA7 ↔ ↔ ↔ ↔ 
AnxA8     
AnxA10 ↔ ↔ ↔ ↔ 
AnxA11  ↔ ↔  
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i portant. I  f ct, hese distinctive membra - and tin-binding prop rti s of AnxA8 aff ct the 
fu ct ni g of late endosom s [84,85] nd in e dot eli l cell , this contributes to co rol the delivery 
of CD 3 from late nd cytic vesicles t  he cell surfac  for leukocyt  recruit e t and ration 
[86 89]. In addition, AnxA8 is asso ated wit  chol ste ol-rich l te endos s, and similarly t  
n 6 overexpress on r NPC  inhibi [19,31,6 ,64,72,73], AnxA8 depl tio  results in cholest  
accumulation in th s compart t [87]. This m y dicate a coordina ed m chanism to control 
xA8 and A xA6 express on l vels a  their rel tive m u  i  t e lat  endosomal c mpartment. 
Along these lines, and as discuss d for A xA6 overexpr sion a d NPC1 deficiency above (see 2.3.), 
it is tempting  speculat  that l te nd som l holest rol accumulatio  trigger d by AnxA8 
downregulati n might c mpr mise adip cyte f nc i n leading to the impr per performance of
molecula  eve ts in caveolae [63,122,123], or related to insuli  signaling and GLUT4 transl cation 
[19,72,73,124]. 
The findi gs described above suggest that cha ges in Anx 8 expression levels m y caus  
cell lar dysfunction However, littl  is so far k ow  if AnxA8 expr ssion l vels correlate with 
etabol c complica ons i  obese f t tissue (Table 1). A xA8 mRNA w s expr ssed i  hu a  adipose 
t ssues a d was si ilar in ubcuta eous and visceral f t d pot  of obese men [88]. In mice,  
mRNA level ere higher i  a ipocyte  than strom l vascular cells. Inter tingly, AnxA8 ex ressi n 
in adipocyt was more ab dant in s bcutanoues fat epots (Ta le 2). This observation d s AnxA8
to the list f candid t pro ins th t are diff r ntially expr ed in he various fat depots, and po sibly 
relevant o fur h r evalu te the deleterious effects of visceral adiposity [88]. 
2.4.5. Other Annexins 
Up t  dat , t is u known if the remaining a nexins AnxA4, A9, A10, A11 d A13 contribute to 
the proper fun ti n ng of adi s  t s ue (Table 1). O t of thos  ann xins, curr t literatur  has 
ass ciated AnxA4 wi h cAMP prod cti , which could b  relevant for lipolysis [90]. Also, r les for 
1 in exocyt sis nd cytokin sis could infl enc  fatty acid rel ase or adipokine secretion [91]. 
Of note, expression dat  for AnxA4, xA9 and AnxA13 i fat w s not p lic y vailable, but 
AnxA10 and A11 ar ind ed expr ss  in fat issu . xA10 expression w s similar in adipocy es 
d stromal vas ular c l s in s bcut ous and intra dominal f t ( l  ). AnxA11 w s mostly 
expr ssed in he stromal vascul r lls of subcut n ou a ipose tissues when c mpared to th  
respective adipocy es a d to intr om l strom vasc lar c lls (Tab e 2). D eren al l vels of
AnxA11 mRNA b twe the cell p pul ti s did not xist in intraabdominal dipo e tissue (T ble 
2). Further studies are evidently r quired t  unrav l their possible functions i  fat tissue. 
Table 2. Expression of annexins A xA3, A5, A7, A8, 10 and A11 mRNA in murine adipose tissues. 
An lysi  of publicly acces ible D A microarray data (G o Pr file ; ataSet Record GDS2818) was 
on  with unpaired Stu ent  t-test. p- lu  < 0.05 was regarded s significant. ,  and ↔ indicate 
higher, lower and unchang d mRNA level , respectively, n adipocytes relative to stromal vascular 
cells (SVC) or in subcutaneous (sc) fat compared to intra bdominal (intra) fat. The mRNA expression 
da a for nx 4, AnxA9 and AnxA13 in fat t ssu  were not available. 
 Subcutaneous Fat 
Adipocyte/SVC 
Intrabdominal Fa  
Adipocyte/ VC 
Adipocytes 
Sc/Intra 
SVC 
Sc/Intra 
AnxA3   ↔ ↔ 
AnxA5   ↔  
AnxA7 ↔ ↔ ↔ ↔ 
AnxA8     
AnxA10 ↔ ↔ ↔ ↔ 
AnxA11  ↔ ↔  
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important. In fact  th se istin t ve memb an - a d t n-binding prop rties of A xA8 affect the
functio i g of lat  endosome  [84,85] and in ndot elial cells, this t ibut s to control the delivery 
of CD 3 from late nd cytic v sicles  the cell surf c for le k cyte recruitmen  and migration 
[86,89]. I  add tio , AnxA8 is ssociated with cholest rol-rich late endos s, and similarly to 
6 ov rexpression or NPC1 inh biti n [19,31,63,64,72,73], A xA8 depleti n results in cholest rol 
accumul tion in this compartm nt [87]. This may indicat  a coordinated chanism to control 
nx 8 and A xA6 xp essio  levels and t r rel tive amou ts n the ate endosomal comp rtment. 
Al ng these line , and as discusse  for AnxA6 verexpression and NPC1 d fici cy above (see 2.3.), 
it is mpting t  sp culate that late end som l holester l accumulation triggered by AnxA8 
dow regulation ight com romise dipocyte function le di g t  th  impr p r performance of 
molecular eve ts in caveolae [63,122,123], or related to insu in signaling d GLUT4 translocation 
[19,72,73,124]. 
The fi dings d sc ibed abo  suggest that cha g s in AnxA8 exp ssion levels may caus  
cell lar dysfunction How ver, ittl is so far kn wn if AnxA8 expressio  level  correlate with 
et b lic comp ic tion  in obese fat tissu  (Tabl  1). A xA8 RNA was expr ss d in human adipose 
tis u s nd was si ilar in subcut eous and visceral fat dep ts of obese m n [88]. In mice,  
RNA levels were higher in dip cyt s than tromal vascular ce ls. Interestingly, AnxA8 ex ression 
i adipocytes was mor  ab nda t i subcutanou s f t depot (T ble 2). This observation adds nx 8 
o th  list o  ca di  p otein  that are i f entially express d in th  various fat d po s, and possibly 
r levant to further valuate the deleterious effects of viscer l adiposity [88]. 
2.4.5. O her Ann xins 
Up to date, t i  unk ow  if the rema i g nexins A xA4, A9, 0, A11 and A13 contribute to 
the proper fun ti ing of a ip s tissue (Table 1). Ou  f tho  a nexins, curre t literature has 
ass cia ed nxA4 with c MP productio , whi h could be e evant for lipolysis [90]. Also, roles for 
1 i  xocytosis and cytokin sis coul  influenc fatty acid release or a i kine secretion [91]. 
Of note, expre sion d ta for AnxA4, 9 nd AnxA13 i  fat w s ot publicly available, but 
nx 10 a d A11 ar  n eed express d fat ti sue. AnxA10 expr sio simil r in adipocytes 
nd st omal va ul r ll  t  and i tr abdomin l fat ( l  ). AnxA11 was mostly 
expres d n the st mal vasc lar cel  of subcutaneous adipose t ssues when c mpared to th  
respective dipocytes and t tr abdom a  st om l vascu r c lls (Table 2). Differenti l levels of 
nxA11 mRNA betwee  the cell populatio s d  n t x t intraabdominal adipose tissue (Table 
2). F ther st dies are evi ently equired to u rav l their po s ble functions in fat tissue. 
Table 2. Expressio  of xins nxA3, A5, A7, A8, A10 a d A11 mRNA in murine adipose tissues. 
Analysis of publicly accessible D A micr r ay data (Geo Profiles; DataSet Re ord GDS2818) was 
done with unpaired Students t-te t. A p-v lue < 0.05 wa  reg rd d as significa t. ,  nd ↔ indicate 
high r, ow r and uncha ged RNA l vels, res ectiv ly, in adip cytes r ative t  stromal vascular 
cells (SVC) or i subcutaneous (sc) fat compar d to intra bdom nal (intra) fat. The mRNA expression 
data for Anx 4, nxA9 nd AnxA13 in fa  tissue were not av ilable. 
 Subcutaneous Fat 
Adipocyte/SVC 
Intrabdominal Fat 
Adipocyte/SVC 
Adipocytes 
Sc/Intra 
SVC 
Sc/Intra 
AnxA3   ↔ ↔ 
AnxA5   ↔  
AnxA7 ↔ ↔ ↔ ↔ 
AnxA8     
AnxA10 ↔ ↔ ↔ ↔ 
AnxA11  ↔ ↔  
AnxA8
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important. In fact, these distinctive membran - and tin-binding prop rties of AnxA8 aff t the
functi ni g of la e endosomes [84,85] a d in endot elial ells, this contributes t  control the delivery
of CD 3 from late e cytic sicles t   ll  f  leukoc te recr it e t and migration
[ ,89]. In a dition, AnxA8 i  associated with cholesterol-ric  late endoso , and similarly to
6 overexp essio  or NPC1 inhibition [19,31,63,64,72,73], AnxA8 d pletio  results in cholest r l
accumulati n in this compartm t [87]. This may indicate a co rdinated m ch ism to control
An A8 and AnxA6 expression levels nd their relative amou ts in the late endos m l o par men .
Along these lines, and as disc ssed for AnxA6 overexpr ssion and NPC1 deficiency above (see 2.3.),
it is tempting to speculate that late end s m l cholest ol accumulati n t iggered by AnxA8
downregulati n might compromise adipocyte function leadi g t  the improper performance of 
molecular eve ts in caveolae [63,122,123], or related to insulin signaling and GLUT4 translocation
[19,72,73,124]. 
Th  findings de cri ed above suggest that cha ge  in AnxA8 expres i n levels may cau
cell lar dysfunction However, littl  is so far known if AnxA8 exp essi n level  correlate with
etabolic complic tions in obese fat tis ue (Table 1). AnxA8 mRNA was expressed in human adipose
tissues and was i lar in subcu a eous and visc ral fat depots f obe e me  [88]. In mice, 
mRNA level  were higher n a ipocytes than stromal vascular cells. Interestingly, A A8 ex ression
in adipocytes was mor  abundant in ubcutanoues fat d pots (Tabl  2). Thi  observat on ad s AnxA8 
to th  list of candidate proteins that are differentially expr ssed in the v rious fat depots, a d possibly 
relevant to further evaluate the deleterious effects of visceral adiposity [88]. 
2.4.5. Other A nexi s 
Up to date, it is unknown if the remaining annexin  AnxA4, A9, A10, A11 and A13 cont bute to
the proper fun ti n ng of adipos  tissue (Ta le 1). Ou  f thos  annexins, cur e t literatu e has
ass cia ed AnxA4 with cAMP productio , which could b  relevant for l polysis [90]. lso, roles for
1 in exocytosis and cytokin is could influ ce fatty acid rele se or adipok e s cret on [91].
Of note, ion data f r AnxA4, An A9 a  AnxA13  f t was ot publicly vail , but
AnxA10 and A11 ar  indeed express d in f t tissue. nxA10 expres io  was imilar in adipocytes
and stromal vasc lar cell  in subcutaneous and intra b o inal fat AnxA11 was mo ly
expressed in the s romal vascu ar cel s of ubcutane u  dipose tissues whe  c mpared to th
respec ve adipocytes and to in a bdominal stromal vascular c lls (Tabl  2). Differential levels of 
AnxA11 mRNA betw en the cell populations did not exist in intraabdominal adipose tissue (Table 
2). Further studies are evidently required to unravel their possible functions in fat tissue. 
Table 2. Expression of annexins A xA3, A5, A7, A8, A10 and A11 mRNA in murine adipose tissues. 
An lysis of publicly accessible D A microa ray ata (Geo Profiles; Dat Set R c rd GDS2818) w s 
done with unpaired Students t-test. A p-val e < 0.05 was rega ded s significant. ,  a d ↔ indicate 
higher, lower and unch nged mRNA levels, respectively, in adipocytes relative to tr mal vascular 
cells (SVC) or in subcutaneous (sc) fat compared to intraabdominal (intra) f . The mRNA expres ion 
data for AnxA4, AnxA9 and AnxA13 in fat tissue were not available. 
 Subcutaneous Fat 
Adipocyte/SVC 
Intrabdominal Fat 
Adipocyte/SVC 
Adipocytes 
Sc/Intra 
SVC 
Sc/Intra 
AnxA3    ↔ 
x 5     
AnxA7 ↔ ↔ ↔ ↔ 
AnxA8     
AnxA10 ↔   ↔ 
AnxA11  ↔ ↔  
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important. In fact, thes distinctive membra - and tin-binding prop r ies of AnxA8 affect the
functioni g of la e en os m s [84,85] and n e dot elial cells, this contributes control the delivery
f CD 3 from late end cytic vesicl s t the cell su fa e for leukocyte r cruitment and migration
[86,89]. In addition, AnxA8 is as oci t d with chol terol-rich late end so s, and similarly to
6 verexpression or NPC1 inhibition [19,31,63,64,72,73], AnxA8 depletio  results in cholest rol
ac u ulation in this ompartm t [87]. This may in i ate a co rdinat d m chanism to control
AnxA8 a d AnxA6 xpression levels a  their relative am unts in the late endosomal compartment.
Along these lin s, and as disc ssed for A xA6 over xpression and NPC1 deficiency above (see 2.3.),
it is tempting to spec lat  that late en om l cholesterol accumulation triggered by AnxA8
downregul tion might comprom se adipocyte funct on leading to the improper performance of 
m l cular eve ts in caveol e [63,122,123], or rel t d to insulin sign ling and GLUT4 translocation
[19,72,73,124]. 
The finding  describ d above sugge t that cha g  i AnxA8 expres ion levels may cau
cell lar dysfu ction However, littl  is so far known if nxA8 expression levels correlate with
etabolic complications in obese fat tis ue (Table 1). AnxA8 mRNA w s expres d in human adipose
tissues and w s i il r i  subcuta ou  and visc ral f t d pots of obe e men [88]. In mice, 
mRNA levels wer  high r in adipocyte  tha stromal vascular cells. I terestingly, AnxA8 ression
in adipocytes wa  more abundan  n subcut n ues fat dep ts (Table 2). This observation d s AnxA8 
o the list of c ndid te ote ns that are differe tially exp essed in the variou  fat depots, and possibly 
relevant to furth  evaluat  he delet ious effects of visceral adipos ty [88]. 
2.4.5. Other A nexi s 
Up to date, it is u k own if the remaining annexi s AnxA4, A9, A10, A11 and A13 cont ibute to
the proper fun n ng of adipos  issue (Table 1). Ou  of thos  annexins, curre t literature has
asso iated nxA4 with cAMP pro uctio , which could be r levant f r lipolysis [90]. lso, roles for
1 in exocytosis and cytokin is co l influence f tty ac d ele se r dipok ne secret on [91].
Of note, expression dat  for A xA4, A xA9 and AnxA13  fat was not p blicly available, but
AnxA10 n A11 are indeed express d in f t ti sue. AnxA10 expr sion was im lar in adipocytes
d stromal v s ular cells in subcutaneous and intraabdom nal fa AnxA11 was mo tly
exp essed in the s romal vascu ar cel s of ubc t eou  adipose t s w en c mpared to th
spec ive adipocytes and o int abdominal st omal vascular c lls (Table 2). Differential levels of 
AnxA11 mRNA be wee  the cell populatio s did not exist in intraabdominal adipose tissue (Table 
2). Further studies are evidently required to unravel their possible functions in fat tissue. 
Tabl  2. Expression of annexins AnxA3, A5, A7, A8, A10 and A11 mRNA in murine adipose tissues. 
Analysis of publicly cc ssible D A mi roarray d t  (G o Profiles; D taSet R c rd GDS2818) w s 
done with unpaired Students t-te t. A p-v lue < 0.05 w s regarded as significa t. ,  and ↔ indicate 
igher, low r and unchang d mRNA levels, respectively, in adipocytes relative to stromal vascular 
cells (SVC) or i  subcutane us (s ) f t compared to intraabdominal (intra) fat. The mRNA expression 
data for AnxA4, AnxA9 and AnxA13 in fat tissue were not available. 
 Subcut ne us F t
Adipocyte/SVC 
Intrabdominal Fat 
Adipocyte/SVC 
Adipocytes 
Sc/Intra 
SVC 
Sc/Intra 
AnxA3    ↔ 
AnxA5     
AnxA7 ↔ ↔ ↔ ↔ 
AnxA8     
AnxA10 ↔   ↔ 
AnxA11  ↔ ↔  
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i portant. In fact, hese distinctive m mb a e- and ctin-b ding properti s of AnxA8 affect the 
fu ct ning of lat  endosom s [84,85] nd in e dot lial ce l , this contributes to control the delivery 
of CD63 from late nd cytic vesicles t  h cell surface for leukocyte recruitme t and migration 
6 89]. In ddition, AnxA8 is associated wit  chol ste ol-rich l te end somes, and similarly to 
xA  overexpr s io  r NPC  inhibi n [19,31,63,64,72,73], AnxA8 depletion results in cholesterol 
accumulation in th  co part t [87]. This may dicate a coordina ed mechanism to control 
xA8 and AnxA6 exp e s on l ve s n  heir relative m u  in th  late endosomal compartment. 
Along these li es, and s discuss d for AnxA6 overexpr ssion a d NPC1 defici ncy above (see 2.3.), 
it is tempting o speculate th t l te dosomal cho ester l accumulation triggered by AnxA8 
d wnregulati n might c mpr mise adip cyt  func ion leading to the improper performance of 
mol cula  events in caveolae [63,1 2,123], or related to ins li  signa ing nd GLUT4 translocation 
[19,72,73,124]. 
The findings described above suggest that ch ges in AnxA8 express on levels may ca se 
cellular dy function However, little is so far kn wn if A xA8 expression le els correlate with 
metabol c c plic ons in ob se fat tissue (Tabl  1). A xA8 mRN  was expres e  in hum  a i se 
t ssues nd w s similar i  ubcutaneous and v sceral fat d pots of bese m n [88]. I  mice, AnxA8 
mRNA level  w re higher i  a po yte  than stromal vascular ce ls. Int r sti gly, AnxA8 expression 
in adipocyt wa  mo  abu dant i  su cuta oues fat ep ts (Table 2). This bservation adds Anx 8 
to the list of ca did t ote ns t t re differ ntially expre ed in the var o s fat depots, and possibly 
relevant o furth r evalu te the deleterious effects of visceral adip sity [88]. 
2.4.5. Other A n i  
Up t  dat , t is u k o  i  the remaining annexins AnxA4, A9, 10, A11 and A13 contribute to 
t e proper fu tion ng of adipo t s ue (Table 1). O t of th s  ann xins, current literature has 
ass ci ed Anx 4 wi h cAMP pr d ction, which cou d b relevant for lipolysis [90]. Also, roles for 
1  exocytosis and cytokin sis could influenc  fatty acid rel ase or adipokine secretion [91]. 
Of not , expression data for AnxA4, nxA9 and AnxA13 in fat w s not pu licly available, but 
AnxA10 and A11 ar  in ee xpr ss in fat t ssue. A xA10 xpression wa sim lar in adipocytes 
d stromal vascul r cells in ubcutaneous nd i tra domin l at (T b e 2). AnxA11 was mostly 
express d n h stromal vascular c lls of subcu n ou dip se t ssu s when c mpared to the 
resp ctive dipocyt s and to intra dominal strom vascular cells (Tab e 2). Dif erential levels of 
AnxA11 mRNA b twee the cell p pul tio s did not exist in intraabdominal dipose tissue (Table 
2). Further studies are evidently r quired t  unrav l their possible functions in fat tissue. 
Table 2. Expression of annexins A xA3, A5, A7, A8, 10 a d A11 mRNA i  murine adipose tissues. 
A lysi  of publ cly acces ible DNA microarray data (Geo Profiles; taSet Record GDS2818) was 
on  with unpaired Stu ent  t-test. A p-v lu  < 0.05 was regarded s significant. ,  and ↔ indicate 
higher, lower and unchang d mRNA level , respectively, n adipocytes relative to stromal vascular 
c lls (SVC) or in subcutaneous (sc) fat compare to intra b i (intra) fat. The mRNA expression 
da a for AnxA4, AnxA9 and AnxA13 in fat t ssu  were not available. 
 Subcutaneous Fat 
Adipocyte/SVC 
Intrabdominal Fa  
Adipocyte/ VC 
Adipocytes 
Sc/Intra 
SVC 
Sc/Intra 
AnxA3   ↔ ↔ 
AnxA5   ↔  
AnxA7 ↔ ↔ ↔ ↔ 
AnxA8     
AnxA10 ↔ ↔ ↔ ↔ 
AnxA11  ↔ ↔  
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important. In fa t, these distinct ve memb ane- a d ctin-b nding properties of AnxA8 affect the 
func io ing of  endo ome  [84,85] and in nd thelial cells, this ibut s to control the delivery 
of CD63 from late ndocytic v sicles o the cel surf c for uk cyte recru tment and migration 
[86,89]. I  add ti n, AnxA8 is ss ciated with ole t rol-rich late endosomes, and si ilarly to 
A xA6 ov rexp ssion or NPC1 inh bition [19,31,63,64,72,73], A xA8 depletion results in cholesterol 
accumulatio  in this compartment [ 7]. This may indicate a coordinated mechanism to control 
AnxA8 and A xA6 x res io  evels and th ir relative amounts in the ate endosomal compartment. 
Along these li , d as discusse  f r AnxA6 verex ression and NPC1 d fici ncy above (see 2.3.), 
it is mpting to speculate that late endosomal holester l ccumulation triggered by AnxA8 
dow regul tion ight com romise adipocyte function leadi g t  th  improp r performance of 
molecular eve ts in c v olae [63,122,123], or related to insu in signaling d GLUT4 translocation 
[19,72,73,124]. 
Th  findings d sc ibed abo suggest that chang s in AnxA8 expression levels may cause 
cellular dysf nction However, littl  is so far know if AnxA8 expression levels correlate with 
met b lic comp ic ti n  i  obese fat ti su  (Tabl  1). A xA8 mRN  was expressed in human adipose 
tis ues nd was imilar in ubcuta eous nd visceral fat epots of obese m n [88]. In mic , AnxA8 
mRNA l vels w re h ghe  in p cytes than str mal vascular ce ls. Intere tingly, nxA8 expression 
i adipocytes was m re ab nd t i s bcutanou s f t depot  (Table 2). This observation adds AnxA8 
o he list o  ca di e protei s tha  are iff rentially expressed in th various fat depots, nd possibly 
relev t to further valuat  the deleterious effects of visceral adiposity [88]. 
2 4.5. Other A nexins
Up to date, t is unknow  if the rema ni g nexins A xA4, A9, 0, A11 and A13 contribute to 
th proper funct ing of adip se tis ue (Table 1). Ou  of those a nexins, current literature has 
associa ed nxA4 with c MP production, which could be re evant for lipolysis [90]. Also, roles for 
A xA11 i oc tos s and cy okinesi  c ul  influenc fatty acid release or adipokine secretion [91]. 
Of no e, expr ssio  da a for nxA4, AnxA9 nd AnxA13 in fat was not publicly vailable, but 
A xA10 a d A11 ar  in eed x ress d fa  ti sue. AnxA10 expr sion was similar in adipocytes 
nd st al va l r c ll  in subcutaneous and i traabdomin l fat (Table 2). AnxA11 was mostly 
xpre ed the st mal v c la  c ll  of subcu neou  a ipose tissu when compared to the 
respective adipocy es and t  ntraabdomi a  st omal vascu ar cells (Table 2). Differential levels of 
nxA11 mRNA betwee  the cell populatio s di  n t x t intraabdominal adipose tissue (Table 
2). F ther st dies are evi ently equired to u rav l their po s ble functions in fat tissue. 
Table 2. Expressio  of xins nxA3, A5, A7, A8, A10 a  A11 mRNA in murine adipose tissues. 
Analysis f publicly accessible DNA micr ar ay data (Geo Profiles; DataSet Record GDS2818) was 
done wi h u p ired Stu ents t-te t. A p-v lue < 0.05 was reg rded as significa t. ,  and ↔ indicate 
high r, ow r and uncha ged RNA l vels, res ectiv ly, in adip cytes re ative to stromal vascular 
cells (SVC) or in subcutaneous (sc) fat compar d to intra bdom nal (intra) fat. The mRNA expression 
data for Anx 4, nxA9 nd AnxA13 in fa  tissue were not available. 
 Subcutaneous Fat 
Adipocyte/SVC 
Intrabdominal Fat 
Adipocyte/SVC 
Adipocytes 
Sc/Intra 
SVC 
Sc/Intra 
AnxA3   ↔ ↔ 
AnxA5   ↔  
AnxA7 ↔ ↔ ↔ ↔ 
AnxA8     
AnxA10 ↔ ↔ ↔ ↔ 
AnxA11  ↔ ↔  
AnxA10
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important. In fact, these distinctive membran - and ti -bind ng prop rti s of A xA8 ff t th
functioni g of la e endosomes [84,85] a d in endot elial ells, this contributes to control the live y
of CD 3 from late end cytic vesicles t  the cell surface f r leukocyte recruitment and migr tion 
[86,89]. In addition, AnxA8 is associated wi h cholest rol-ric lat  nd so s, and similarly to
6 overexpressio  or NPC1 inhibition [19,31,63,64,72,73], AnxA8 d pletion r sults in chole t r l
accumulation in this compartm t [87]. This may indicat  a c rdi t d ch ism to contr l
AnxA8 and AnxA6 expression levels and th ir relative amou s in t e late endos m l o par men .
Along these lines, and as disc ssed for A xA6 overexpr ssion and NPC1 def ciency above (see 2.3.),
it is tempting to speculate that late end s l chol sterol ccumulati n trigg red by AnxA8
downregulation might compromise adipocyte functi n l ading t  th  improper performance of 
molecular eve ts in caveolae [63,122,123], or related t insul  signaling a d GLUT4 translocation
[19,72,73,124]. 
The findings descri ed above sugg t that cha ge  in A xA8 expres ion l vels may c u
cell lar dysfunction However, littl  i  so far known if AnxA8 ex essio  l v l  o rel te with
etabolic complications in obese fat tis ue (Tabl  1). Anx 8 mRNA was expres d in human adipose
tissues and was i lar in subcu a e us a d vis eral fat d p t of obese men [88]. In mice, 
mRNA levels were higher n adipocy s than stromal vascular cell . I terestingly, A xA8 ssion
in adipocytes was more abundant in subcutanoues fat d ots (Tabl  2). This observatio  add  Anx 8 
to the list of candidate proteins that are differentially expressed in the various fat depots, and possibly 
relevant to further evaluate the deleterious effects of visceral adiposity [88]. 
2.4.5. Other Annexins 
Up to date, it is unknown if the remaining an exins AnxA4, A9, A10, A11 and A13 c t ute to
the proper fun ti n ng of adipos  tissue (Tabl  1). Ou  of thos  a exi s, urre t literat e has 
associated AnxA4 with cAMP productio , which could b  r l vant lipol sis [ 0]. lso, roles fo
1 in exocytosis and cytokin is could influ nce fatty cid release o  adipok ne s cret on [91].
Of note, expression data f r AnxA4, AnxA9 d AnxA13  f t as ot p blicly vail but
AnxA10 and A11 ar  indeed express d in f t tissu . AnxA10 expr s io was simila  i  adip ytes
and stromal vas ular cells in subcutaneous and intraabdominal fat AnxA11 was mo tly
expressed in the s romal vascu ar cel s of ubc ta e u  dipose tissu s w  c mpared to th
respec ive adipocytes and to in aabdominal stromal v scular c lls (Table 2). Differ nt al levels of 
AnxA11 mRNA between the cell populations did not exist in intraabdominal adipose tissue (Table 
2). Further studies are evidently required to unravel their possible functions in fat tissue. 
Table 2. Expression of annexins A xA3, A5, A7, A8, A10 and A11 mRNA in m rine adipose tissues. 
Analysis of publicly accessible D A microarray data (Geo Profiles; D taSet R c rd GDS2818) w s 
done with unpaired Students t-test. A p-val e < 0.05 was r garded s significant. ,  d ↔ indicate 
higher, lower and unchanged mRNA levels, respectively, i  adipocytes relative to stromal vascular 
cells (SVC) or in subcutaneous (sc) fat compared to intraabdominal (intra) fat. The mRNA expression 
data for AnxA4, AnxA9 and AnxA13 in fat tissue were not available. 
 Subcutaneous Fat 
Adipocyte/SVC 
Intrabdominal Fat 
Adipocyte/SVC 
Adipocytes 
Sc/Intra 
SVC 
Sc/Intra 
3    ↔ 
nx 5     
nx 7 ↔ ↔ ↔ ↔ 
AnxA8     
nx 10 ↔   ↔ 
AnxA11  ↔ ↔  
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important. In fact, thes distinctive membra - nd ti -binding pr p ies of nxA8 aff c  the
functioni g of la e en os mes [84,85] a d  endot elial cells, thi  ontributes ontrol the elivery
f CD 3 from late end cytic v sicl to the cell u face for leukocyte r cr itment and migratio
[86,89]. In additio , AnxA8 is as oci ted w th chol sterol-r ch l te e d so s, a  simil rly to
6 verexpression or NPC1 i hibition [19,31, 3,64,72,73], AnxA8 depletio  results i  cholest rol
ac u ulation in this co partm t [87]. This m y in i ate a co rdinat d m chanism t  co trol
AnxA8 a d AnxA6 xpressio level  and heir elative am unts in th  lat  endosomal compartment. 
Along these lines, and as disc ssed for A xA6 over xpressi n and NPC1 deficiency above (see 2.3.),
it is tempting to speculat  that late end om l holester l accumulati n trig ered by nx 8
downregulation might comprom se adipocyte funct on leading to the improper performance of 
mol cular eve ts in cav ol e [63,122,123], or rel t d to insulin sign li g and GLUT4 translocation
[19,72,73,124]. 
The finding  described above suggest that cha g  i AnxA8 e pres ion level may cau
cell lar dysfu c ion However, lit l  is so f r  if A xA8 xpre sion levels cor late with
etabolic complications in obese fat tis u (Table 1). AnxA8 mRNA w s xpres d in human dipose
tissues and w s i il r in ubcut e u  and vi eral f t d pots of obe e men [88]. In mice,
mRNA levels we high r in adipocyte  tha stromal vascular cell . I teresti gly, An A8 ex re si n
in adipocytes was more abundan n subcu n ues fa  depo s (Tabl 2). This observation adds AnxA8 
o the list of c ndidate p ote ns that are differentially expressed in the var ou  fat depots, and po sibly 
relevant to furth  evaluat  he delet ious effe ts of vi ceral adiposity [88]. 
2.4.5. Other Annexins 
Up to date, it i  u k own if the remaini g an exins A xA4, A9, 10, 11 a  13 co t ibute o
the proper fun n ng of a ipos  t sue (Table 1). Ou of thos  an exins, rr t li er ture has
asso iated nxA4 with cAMP pro uction, which could be elevant f r lipolysis [90]. Also, role  for
1 in exocytosis an  cytoki is ul infl ence f tty ac d el ase r dipok ne ecret on [91].
Of note, expression dat  for A xA4, AnxA9 and A xA13 n fat w s not p b icly avai able, but
AnxA10 and A11 are ind ed expres d in fa  t sue. A xA10 ex ressi n w s imilar in dipocy es
and stromal v s ular ells in sub utaneo s and intraab om al fa AnxA11 was mo tly
expressed in the s romal vascu ar c l s of ubc tan ou  adipose ti sue  w e  c mpared to the
spec ive adipocytes and o int aabdom nal stromal ascular c lls (Table 2). Differen al levels of 
AnxA11 mRNA betwee  the cell populatio s did not exist in intraabdominal adipose tissue (Table 
2). Further studies are evidently required to unravel their possible functions in fat tissue. 
Tabl  2. Expression of annexins AnxA3, A5, A7, A8, A10 and A11 mRNA in murine adipose tissues. 
Analysis of publicly cc ssibl  D A microarray d t  (G o Profiles; D taSet R c rd GDS2818) w s 
done with unpaired Students t-te t. A p-valu  < 0.05 w s regarded as significa t. ,  and ↔ indicat  
igher, lower and unchang d mRNA levels, respectively, in adipocytes relative to stromal vascular 
cells (SVC) or in subcutane us (sc) fat compared to intraabdominal (intra) fat. The mRNA expression 
data for AnxA4, AnxA9 and AnxA13 in fat tissue were not available. 
 Subcut ne us F t
Adipocyte/SVC 
Intrabdominal Fat 
Adipocyte/SVC 
Adipocytes 
Sc/Intra 
SVC 
Sc/Intra 
nx 3    ↔ 
nx 5     
nx 7 ↔ ↔ ↔ ↔ 
AnxA8     
nx 10 ↔   ↔ 
AnxA11  ↔ ↔  
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i portant. In fact, hese distinctive m mb a - and tin-b ding pro ti s of A xA8 affect the
fu ct ni g f la  endos m s [84,85] nd in e dot lial c l , this co ributes to control the delivery
of CD 3 fr m late nd cytic vesicles t  e cell surface for leukocyte recruitment  mig ation
6 89]. I  ddition, AnxA8 is as o iated wit  chol ste l-rich l t  endoso es, nd similarly to
6 overexpr s io  r NPC  inhibi [19,31,63,64,72,73], A xA8 depletion results in chol st rol
accumulatio  in th  ompart t [87]. Thi may dicate a coordina e m chanism to control
xA8 and AnxA6 exp ess on l ve s a  heir rel tive m u  i  t  lat  en osomal compartment.
Along thes  li ,  s di cuss d for AnxA6 overexpr ssion d NPC1 defici ncy above (see 2.3.), 
it is tempting  sp culat t t l te som l cho ester l accumulatio  trigg red by A xA8
downregulati n might c mpr mise adip cyte func ion l ading to the impr per p rform nce of 
ol cula  eve ts in caveolae [63,122,123], or elated to ins li signa ing nd GLUT4 t an l catio
[19,72,73,124]. 
The findings described above suggest that ch ges in Anx 8 xpres on levels may cau
cell lar dy func ion However, littl  i  o far kn wn if A xA8 expressio levels corr late with
etabol c c plic o s in obese fat tissue (Table 1). A xA8 mRN  w  exp ess d i  huma  adipose
t ssu s d w s i ilar in subcu a eous and v sceral fat d pot of b se men [88]. In mice,  
mRNA level  w re higher in a ipoc te  than tr mal vascular cells. Inter stingly, AnxA8 ex ressi n
in adipocyt was mo  ab nt in s bcu anoues fat epots (Table 2). This observa ion adds AnxA8 
to the list of candid t proteins th t are diff r ntially expre ed i  the various fat depot , and possibly 
relevant o furth r evalu te the deleterious effects of visceral dip sity [88]. 
2.4.5. Other Annexins 
Up t dat , t is u kno i  th  remaining a nex ns nxA4, A9, 10, A11 d A13 cont ibute to
the proper fu ti ng of adip t s ue (Table 1). O  of th s  an xi s, curr t literature h s
ass ci ed Anx 4 wi h cAMP prod c io , wh ch cou d b elevant for lip lysis [90]. Also, roles for
1 in exocytosis and cy oki is coul  i fluenc  fatty acid rel ase or adipok ne secret on [91].
Of not , expression dat  for A xA4, nxA9 and nx 13 fat w  not pu li ly av ilable, bu
x 10 and A11 r  in eed xp ss d in f t tissu . A xA10 xpr ssion was similar in ipocytes
d stro al vas ular c lls i  ubcut eous a d intr dominal t AnxA11 was mo tly 
expressed n h s omal vascu ar c l s of ubcu n ou ipose tissues when c mpared to th
resp c ive dipocytes and to nt domi al strom vasc lar c lls (Tab e 2). Dif erential levels of 
AnxA11 mRNA b twee the cell p pul tio s did not exist in intraabdominal dipose tissue (Table 
2). Further studies are evidently r quired t  unrav l their possible functions in fat tissue. 
Table 2. Expressi  of annexins A xA3, A5, A7, A8, 10 a d A11 mRNA in murine adipose tissues. 
A lysi  of publicly acces ible D A microarray data (G o Profil s; taSet R c rd GDS2818) w s 
on  with unpaired Stu ent  t-test. A p-v lu  < 0.05 was reg rded s significant. ,  and ↔ indicate 
higher, lower and unchang d mRNA level , respectively, n adipocytes relative to stromal vascular 
cells (SVC) or in subcutaneous (sc) fat compared to intra bdominal (intra) fat. The mRNA expression 
da a for Anx 4, nxA9 and AnxA13 in fat t ssu  were not available. 
 Subcutaneous Fat 
Adipocyte/SVC 
Intrabdominal Fa  
Adipocyte/ VC 
Adipocytes 
Sc/Intra 
SVC 
Sc/Intra 
3     
nx 5     
nx 7    
AnxA8     
AnxA10 ↔ ↔ ↔ ↔ 
AnxA11  ↔ ↔  
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importa t. In fa t, t  distin t ve m mb an - a d tin-b nding pro rties of A xA8 affect the
func i i g of  e do ome  [84,85] and in nd t elial cells, this ibut s to con rol the delivery
of CD 3 f om late nd cytic v sicles  t  cel surf c for uk cyte recru tment d migration
[86,89]. I  add tion, AnxA8 is ss ciated with ole t rol-rich late endos mes, and similarly to
A A6 ov rexp sion or NPC1 inh bition [19,31,63,64,72,73], A xA8 depletion resul s in chole t rol
accumul tio  i  this com artm nt [87]. This m y indic te a coordinated m chanism to control
AnxA8 and A xA6 xpres i  evels and th i  rel tive a ounts in the at  en osomal compartment.
Along these lin , a d as discuss  f r AnxA6 verex ressio  and NPC1 d fici ncy above (see 2.3.),
it is mpting to spec l te that late end som l ho ester l ccumulation trigger d by A xA8
ow regulation ight com romise adip cyte function le di g t  the i prop r performance of 
olecula  eve ts in c v olae [63,122,123], or related to in u i  signaling d GLUT4 translocation
[19,72,73,124]. 
The f dings d sc ibed abo suggest that changes in AnxA8 expres ion levels may cau
cell lar dysfunction Howeve , littl  is so far kn wn if nx 8 express on l vels correlate with
met b lic c mp ic tion  i  obese fat tis u  (Tabl  1). A xA8 mRNA was exp s d in h man adipose
tis u s nd a i ilar in ubcu eous and visceral fat ep t  of obe e m n [88]. In mice, A A
mRNA l vels w re h ghe  i  p cyt s than stromal vascular ce ls. Interestingly, AnxA8 ex ression
i  adi ocytes was mor  ab nd nt i subcutanou s f t depot (T ble 2). This obser tion adds AnxA8 
o the list o ca did  proteins tha  are iff rentially expr ssed in th  v rious f t depots, and possibly 
elevant to further valuate the d leterious effects of visceral adiposity [88]. 
2.4.5. Other Annexins 
Up to ate, t is unkn w  if the rem ni g nexi s xA4, A9, 0, A11 a d A13 cont ibute to
th proper fun ti ng of a i se tis ue (Table 1). Ou  f thos  a nexins, c rr t lit rature has
ass cia ed nxA4 with cA P prod ctio , which could be re evant f r lipolysis [90]. Also, roles for
A A 1 i ocytosi d cytokin i  c uld influenc fatty aci  relea e or a ipok ne secret on [91].
Of note, e re io  data f r 4, AnxA9 and A xA13  fat was not publicly av ilable, but
x 10 a d A11 ar  in eed ex es d fat ti sue. AnxA10 expr sio  was similar in adipocytes
nd st l v ular c ll  i  subcutaneou  d i tr ab omin l fat AnxA11 was mo tly
xpres d n the s ma  v sc  cel  of ubcutaneou  a ipose tissues when c mpared to th
respec ive adipocytes and t  nt abdomi a  t omal vascu ar c lls (Table 2). Differential levels of 
nxA11 mRNA betwee  the cell populatio s di  n t x t intraabdominal adipose tissue (Table 
2). F ther st dies are evi ently equired to u rav l their po s ble functions in fat tissue. 
Table 2. Expressio  of xins nxA3, A5, A7, A8, A10 a d A11 mRNA in murine adipose tissues. 
Analysis of publicly accessible D A micr ar ay data (Geo Profiles; DataSet R cord GDS2818) w s 
done with unp ired Students t-te t. A p-v lue < 0.05 was reg rded as significa t. ,  and  indicate 
high r, ow r and uncha ged RNA l vels, res ectiv ly, in adip cytes re ative to stromal vascular 
cells (SVC) or in subcutaneous (sc) fat compar d to intra bdom nal (intra) fat. The mRNA expression 
data for Anx 4, nxA9 nd nxA13 in fa  tissue were not available. 
 Subcutaneous Fat 
Adipocyte/SVC 
I trabdominal Fat 
Adipocyte/SVC 
Adipocytes 
Sc/Intra 
SVC 
Sc/Intra 
3     
nx 5     
nx 7     
AnxA8     
AnxA10     
AnxA11     
1
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important. In fact, these distinctive memb - d actin-bind g pro ti s of A xA8 aff ct th
functioning of late e omes [84,85] and in end th ial cells, th s c n ibut s to ontr the liv ry
of CD63 from late ndocytic v sicles to t  cell surfac  fo  ukocy  r cruitmen nd migrati
[86,89]. In addition, A xA8 is as oci ted with chole terol-rich late end s es, and similarl t
AnxA6 overexpression or NPC1 inhibitio [19,31,63,64,7 73], AnxA8 d pl ti  e ults i  ch l ste o
accumulation i  this compartment 87]. This may indicate  coord ated e hani m to cont l 
AnxA8 and AnxA6 exp ssion levels a d the r r l tiv  mo nt  in h l t en omal compartme t.
Along these lines, a d as discussed for AnxA6 o rexpr sio  and NPC1 deficie y bove (see 2.3.),
it is tempting to spe ulat  that la e end somal chol st ol accumul io trigger d by xA8
downregulation might compro ise ad p cyt  f c i l a i g to h  i pr er perf rm c  f
olecular vents in cav ola  [63,122,123], r r l te to in li  signalin  and GLUT4 translocat
[19,72,73,124]. 
The findi gs d sc ib d above sugg st hat ch ng s in A xA8 x r sio  l vels may c use
c lular dysfunction However, little is so ar kn wn if Anx 8 xpr ssi n le els cor elat  with 
metabolic complicati ns in obese fat tissu  (Table 1). AnxA8 mRNA was xpress d in human adipose 
tissues and was simil r in subcuta eous d visc ral f t depots of obese men [88]. In mice, A xA8 
mRNA levels were higher in adipocytes than stromal vascular cells. Interestingly, AnxA8 expression 
in adipocytes was more abundant in subcuta oues fat depo s (Table 2). This observation adds AnxA8 
to the list of ca didate pr teins that are differentially expressed in the various fat dep ts, a d possibly 
relevant to further evaluate the deleterious effects of visceral adiposity [88]. 
2.4.5. Oth r Annexins 
Up to dat , it is unknown if the r maining n xi  xA4, A9, A10, A11 and A13 co tribut  to
the proper functioning of a ipos tis u  (Table 1). Out of tho e ann xi s, current lit ature h
s ociated AnxA4 with cAMP production, which could b  r lev t f r li oly s [90]. Als , rol s f
in exocytosis a d cytokinesis co ld influe c  f tty cid re a e or ipoki e s creti n [91].
Of note, xpression d ta for AnxA4, AnxA9 a d AnxA13 in fa  w s not pub icly avail l , but 
0 and A11 are indeed expressed in fat tissue. AnxA10 expressi  was similar i  adip cytes 
and stromal vascular cells i  subcutane us a d intraabdominal fat (Table 2). AnxA11 was mostly 
expressed in the strom l vascular cells of subcutaneous adip se tissues when compared t  the 
respectiv adipocytes an  to intraabdominal stromal vascular cells (Table 2). Differential levels of 
AnxA11 mRNA between the cell populations did not exist in int aab ominal a ipose tissue (Table 
2). Furth r studies are evide tly r quired t  unravel their possible functions in f t tissue. 
Table 2. Exp ession of nexins AnxA3, A5, A7, A8, A10 d A11 mRNA in murine dipose tis ues. 
An lysis of publicly accessible DN  microarr y data (Geo Pr file ; D taSet Recor  GDS2818) was 
done with unpaired St dents t-test. A p-value < 0.05 was regarded as significant. ,  and ↔ indicate 
higher, lower and unchanged mRNA levels, respectively, i  adipocytes relative to stromal vascular 
cells (SVC) or in subcutaneous (sc) fat c mpared to intraabdominal (i tra) fat. The mRNA expression 
data for AnxA4, AnxA9 and AnxA13 in fat tissue were not available. 
 Subcutaneous Fat 
Adipocyte/SVC 
Intrabdominal Fat 
dipocyte/SVC 
Adipocytes 
Sc/Intra 
SVC 
Sc/Intra 
nx 3     
nx 5     
AnxA7 ↔   ↔ 
AnxA8     
AnxA10 ↔ ↔ ↔ ↔ 
AnxA11  ↔ ↔  
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important. In f t, these distinctiv  membra e- n  cti -binding rop ti s of nxA8 aff ct
functioning of late endos mes [84,85] a d in endoth li l cells, this con ributes to co rol th elivery 
of CD63 fr m late end cytic ves cle  to the cell surfac  fo  leukocyt  r cr it ent and grati n 
[86,89]. I  additio , AnxA8 is as oc te  with ch l ster l-rich late endos mes, nd similarly to 
nxA6 overexpress on r NPC1 inhibiti  [19,31,63,64,72,73], A xA8 depl ti  r sults  chol st  
ac mulatio  in this part ent [87]. This m y in icate a coordin ted echanis  to control
nxA8 and A x 6 expression l vels and their el tive amo t  i the lat  end somal c mpartme t. 
Along hes  li e , and as discussed for A xA6 over xpr s n nd NPC1 deficien y above (see 2.3.), 
it is tempting to speculate that late endos mal h lest rol accumul tion tri ger d by AnxA8
downregulatio  i ht c mprom e adip cyte fu i  leading  th i pr per p rfor ance of 
molecular eve ts in caveola  [63,12 ,123], or l ted t  insulin signali g and GLUT4 t nsl ca ion 
[19,72,73,124]. 
The findi gs esc ibed above ugge t that ch g s i  AnxA8 xpress on levels m y cause 
cellular dysfunction How ve , tle i  so far know if A xA8 expre ion levels cor lat  with 
m t olic omplicat ons i  ob se fat ssue (T le 1). AnxA8 mRNA was xpr ssed in hu  adipose 
t ssu s a  was similar in subcuta ous and visce l f t d pots of obese men [88]. I  mic , A xA8 
mRNA level e higher in adipocytes tha  stro l v s l r cell . Intere tingly, AnxA8 expre ion
in adip cytes was mor  abundant i  s bcu noues fat depots (Table 2). Thi  o servation d s A xA8
to the list f candidate pro ein  at re differe tia y expr s ed in he v rious fat depots, and possi ly
relevant to further evaluate the deleterious effects of visceral adiposity [88]. 
2.4.5. Other A nexi s 
Up to dat , it is unknow  if th rem ining an xins AnxA4, A9, 10, A11 and 13 co tribute t  
the proper functi ni g of a i o e tis ue (T bl 1). Ou  f t os an exin , urr nt lit ratur  ha  
a sociated AnxA4 with cAMP productio , hich c uld b  relevan  for li ol si  [90]. Al , r le  for 
A xA11 in exocyt sis cytokine is ould i fl ence f tty cid rele se or dipokine secret on [91]. 
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AnxA10 and A11 are ind ed expre se  in f t tissue. nx 10 expression wa  si ilar in dipo y es 
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AnxA11 mRNA betwe n the cell populat ns did n t xis  i  intraabdo inal dipo  tissue (Table 
2). Further studies are evidently req ired to unravel their possible functions in fat tissue. 
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data for AnxA4, AnxA9 and AnxA13 in fat tissue were ot available. 
 Subcutaneous Fat 
dipocy e/SVC 
Intrabdominal Fat 
Ad pocyte/SVC 
Adipocytes 
Sc/Intra 
SVC 
Sc/Intra 
nx 3     
nx 5   ↔  
nx 7     
nx 8     
AnxA10 ↔ ↔ ↔ ↔ 
AnxA11  ↔ ↔  
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 14 of 22 
 
important. In ct, thes  di tinctiv  e brane- and c in-bi d ng pro rties of A xA8 aff ct the 
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cell lar dysfunction However, littl  is so far kn w  if nxA8 expres ion levels correl te with 
et bolic complications i  b s  fa  tis ue (Table 1). A x 8 mRNA was express d in huma  se 
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Of note, expressio  d ta for AnxA4, AnxA9 and AnxA13 i  fat was not publicly available, but 
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3. Conclusions
Annexins bind negatively charged phospholipids and cholesterol in a Ca2+-dependent and
reversible manner, and together with transient interactions with membrane-associated proteins,
this contributes to dynamic changes in the structural and functional organization of membrane
domains [23,25–31,64,93,94,109,116,118,137,157]. As outlined in this review, this membrane organizing
function of annexins also seems highly relevant for adipose tissue physiology. In particular, AnxA2
has been linked to the insulin-dependent translocation of GLUT4 as well as CD36-mediated fatty
acid uptake [51,57,59], the latter providing a protective function in the postprandial state. Likewise,
AnxA6 affects signaling events relevant for lipid storage and, importantly, regulates adiponectin
release, an essential adipokine in metabolic health [61,62,64,68,70]. Alternatively, the most prominent
disease-preventing functions of AnxA1 in adiposity, glucose and lipid homeostasis are facilitated
through its extracellular activity as a FPR2 ligand [34,37,39,41,42,45,104]. While functions and
mechanistic insights for these three annexins in fat tissue are emerging, up until now all other
annexins have been barely studied in the context of obesity, adipocyte physiology, and adipokine
production. Future experiments, combining biochemical and imaging techniques in overexpression
and knockdown cells and animal models, together with high-throughput and innovative technologies
addressing transcriptomics, proteomics, lipidomics, and metabolomics in adipocyte-specific knock-out
models may identify the impact of individual annexins in the molecular pathways that contribute to
dysregulated adipokine production and fat cell function in obesity.
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